Single-chain polypeptide activated in use
By designing single-chain polypeptides at protease cleavage sites in specific sites, safety and effectiveness issues in the prior art are solved, and the effects of muscle relaxation, wrinkle reduction and body shaping are achieved.
Patent Information
- Application Number
- PCT/CN2024/096882
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
The prior art does not provide a single-strand polypeptide that can be produced and used safely and effectively for the treatment of muscle spasms, dynamic wrinkles and body contour shaping.
A single-stranded polypeptide activated at a specific site of use is designed, and is cleaved by a highly specific cleavage site at a specific site of the human body, and is converted into an activated form for inhibiting the release of information substances, including the first domain, The intermediate amino acid sequence region and the second domain ensure safe and efficient use in specific areas.
It realizes efficient activation in specific parts, improves the safety and convenience of use of products, avoids the risk of poisoning caused by accidental ingestion or improper use, and ensures the safety of production and use.
Smart Images

Figure CN2024096882_05122024_PF_FP_ABST
Abstract
Description
Single-chain peptide activated at the time of use Technical Field
[0001] The present invention belongs to the field of biotechnology, and specifically relates to a single-chain polypeptide that is activated when used, and specifically relates to a single-chain polypeptide, its corresponding application, a nucleic acid encoding the single-chain polypeptide, and a preparation method thereof. Background Art
[0002] Currently, some toxin molecules with specific cleavage components can achieve applications such as the following:
[0003] (1) Therapeutic applications: treatment of hemifacial spasm, essential blepharospasm, spasmodic torticollis, spastic cerebral palsy, post-stroke limb spasm, tremor and other types of dystonia;
[0004] (2) Application in minimally invasive plastic surgery:
[0005] Including wrinkle removal of various dynamic wrinkles such as frown lines, forehead lines, crow's feet, etc.; beautification of facial contours such as eyebrow height adjustment, mental muscle relaxation, mandibular margin lifting, neck line injection, etc.
[0006] Reshape the body contours by reducing the masseter muscle, gastrocnemius muscle, trapezius muscle, etc.
[0007] However, there is currently no product that can be safely and effectively produced and used to achieve the aforementioned effects.
[0008] Summary of the Invention
[0009] The present invention provides a single-chain polypeptide which is highly activated and attenuated upon entering a specific site of use and can be produced more safely and conveniently, its corresponding application, nucleic acid encoding the single-chain polypeptide, and its preparation method.
[0010] To this end, the present invention provides the following technical solutions:
[0011] The present invention provides a single-chain polypeptide, characterized in that it includes: a first structural domain, an intermediate amino acid sequence region, and a second structural domain, wherein the intermediate amino acid sequence region is between the first structural domain and the second structural domain, and the intermediate amino acid sequence region sequence contains at least one first enzyme cleavage site, and the first enzyme cleavage site is designed to be highly specifically cleaved by a first protease present in a specific part of the human body. After the single-chain polypeptide is cleaved by the first protease at the first enzyme cleavage site, it is converted into an activated form that can inhibit the release of information substance.
[0012] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first domain has a molecular weight of approximately 50 kDa, the second domain has a molecular weight of approximately 100 kD, and the first domain has cleavage activity.
[0013] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the information substance is an intercellular information substance, preferably any one of a neurotransmitter, an endocrine hormone, a local chemical mediator and a gas signal molecule, and more preferably the information substance is acetylcholine.
[0014] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first domain is a non-toxic cellular protease or a fragment thereof that can cleave the protein of the exocytic fusion apparatus of the target cell; the second domain has a binding portion and a transport portion, the binding portion can bind to the target cell receptor and enter the endosome of the target cell through receptor-mediated endocytosis, and the transport portion can transport the first domain into the cytosol of the target cell;
[0015] Preferably, the first enzyme cleavage site is between the first domain and the transport portion, and / or the binding portion is carboxyl-terminal and has a molecular weight of about 50 kD, and the transport portion is amino-terminal and has a molecular weight of about 50 kD;
[0016] Another preferred embodiment is that the protein of the exocytosis fusion apparatus is a neuronal snare protein, and / or the target binding site is a receptor on the presynaptic membrane of a neuron.
[0017] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first domain comprises at least a portion of the L chain of the Clostridium neurotoxin:
[0018] Preferably, the portion of the Clostridium neurotoxin L chain is the neurotoxin L chain of one of Clostridium botulinum subtypes A, B, C, D and E or is derived therefrom, and / or the first domain comprises an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to SEQ ID NO: 10, or an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of 11-16 excluding a naturally occurring enzyme cleavage sequence; and / or
[0019] The second domain comprises at least a portion of a Clostridium neurotoxin H chain, preferably the portion of the Clostridium neurotoxin H chain is a neurotoxin heavy chain of one of the following: Clostridium botulinum subtype A, Clostridium botulinum subtype B, Clostridium botulinum subtype C, Clostridium botulinum subtype D, Clostridium botulinum subtype E, Clostridium botulinum subtype F, Clostridium botulinum subtype G, Clostridium pasteurian (C. Baratii) and Clostridium butyricum (C. Butyricum); or the portion of the Clostridium neurotoxin H chain is a neurotoxin H chain of Clostridium tetani (C. Tetani) or is derived therefrom, and / or
[0020] The second domain comprises an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 17-23.
[0021] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein, the number of amino acids in the linker (L1) between the first domain and the intermediate amino acid sequence region is 0-20 or 0-10 amino acids or 0-5; and / or the number of amino acids in the linker (L2) between the intermediate amino acid sequence region and the second domain is 0-20 or 0-10 amino acids or 0-5.
[0022] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first protease is not a protease present in the human digestive tract,
[0023] Preferably, the specific part of the human body is human skin tissue, and / or at least one of the first proteases is selected from the following:
[0024] Any one or more of epidermal-specific kallikrein (KLKs) proteases (e.g., KLK5, KLK6, KLK7), SASPase proteases, Caspase proteases (e.g., Caspase-14), Furin proteases, and variants thereof that retain enzymatic activity; and / or,
[0025] The first enzyme cleavage site contains an amino acid sequence that is at least 50%, 60%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 1-4, SEQ ID NO: 50 and SEQ ID NO: 51.
[0026] In SEQ ID NO: 50 and SEQ ID NO: 51, "X" in RXXR and RRXX is any amino acid, preferably, XX in RXXR is RK, TK or TR; "XX" in RRXX is SV or KR.
[0027] The single-chain polypeptide provided by the present invention also has the following characteristics, and further comprises: any one or more of a signal peptide for increasing expression, a quantitative protein for quantification, and a tag protein. Further, the signal peptide, the quantitative protein, and the tag protein are respectively defined as follows: the signal peptide comprises an amino acid sequence having at least 80%, 85%, 90%, 99% or 100% identity with SEQ ID NO: 24; the quantitative protein is a fluorescent protein;
[0028] The tag protein is one or more of a His tag, a GST tag, an MBP tag and a Strep-tag II tag.
[0029] The single-chain polypeptide provided by the present invention also has the following characteristics, and further comprises: two second enzyme cleavage sites located at the N-terminus of the first domain and the C-terminus of the second domain, respectively, and the second protease that cleaves the second enzyme cleavage site cannot cleave the first enzyme cleavage site.
[0030] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein, the first enzyme cleavage site and / or the second enzyme cleavage site are usually not cleaved by the protease that contacts the single-chain polypeptide when the single-chain polypeptide is expressed in the host cell in vivo or synthesized by an in vitro synthesis system involving cell extracts from host cells.
[0031] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the second enzyme cleavage site is designed to be highly specific for the second protease, preferably, the second protease is selected from non-human enterokinase, tobacco etch virus protease, protease derived from Bacillus subtilus, protease derived from Bacillus amyliquifaciens, protease derived from rhinovirus, papain, homologs of insect papain or homologs of crustacean papain; and / or
[0032] The second enzyme cleavage site comprises an amino acid sequence that is at least 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 5-9.
[0033] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the intermediate amino acid sequence region sequence further includes XTXS, wherein X is not a K amino acid, preferably: X is a Q amino acid; and / or
[0034] The structure of the intermediate amino acid sequence region sequence from N-terminus to C-terminus is:
[0035] XTXS-linker (L3) - at least one first enzyme cleavage site, further, the number of amino acids in L3 is 0-20 or 0-10 or 0-5, and further, the number of the first enzyme cleavage site is 1.
[0036] The single-chain polypeptide provided by the present invention also has the following characteristics: when the second domain contains an amino acid sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 17, the lysine at the position corresponding to the 423rd position of the amino acid sequence of the second domain is mutated to a non-lysine.
[0037] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein, the first domain, the middle amino acid sequence region and the second domain are connected from the N-terminus to the C-terminus; and / or when there are multiple first enzyme cleavage sites, the multiple first enzyme cleavage sites are sequentially connected from the N-terminus to the C-terminus, all the first enzyme cleavage sites have the same cleavage site or the first enzyme cleavage sites are different, and the number of amino acids in the linker (L4) between the multiple cleavage sites is 0-20 or 0-10 amino acids or 0-5.
[0038] The present invention also provides an application of the single-chain polypeptide as described above: the application includes any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms.
[0039] The present invention also provides a use of the single-chain polypeptide as described above in the preparation of products or medicines for specific purposes: the specific purposes include any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms.
[0040] The present invention also provides a single-chain polypeptide product or medicine, characterized by comprising: the single-chain polypeptide as described above, preferably, the product or medicine has applications including any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms;
[0041] Another preferred embodiment is that the product or medicine is applied to a specific part of the human body by smearing, spraying, external application or injection.
[0042] The present invention also provides a nucleic acid, characterized in that it comprises: a nucleotide sequence encoding the single-chain polypeptide as described above.
[0043] The present invention also provides a vector, characterized in that it comprises: the nucleic acid as described above.
[0044] The present invention also provides a host cell, characterized in that the aforementioned nucleic acid is integrated and / or the aforementioned vector is included.
[0045] The host cell provided by the present invention also has the following characteristics: the host cell is derived from a prokaryotic cell or a eukaryotic cell, and further, the cell is selected from the following group: a combination of one or more of Escherichia coli cells, human cells, Chinese hamster cells, ovary cells, insect cells, wheat germ cells, rabbit reticulocytes and yeast cells.
[0046] The host cell provided by the present invention also has the following characteristics: wherein the host cell is selected from yeast cells, further, the yeast cell is selected from: a combination of one or more of Saccharomyces cerevisiae and Kluyveromyces yeasts, and in another preferred embodiment, the Kluyveromyces yeast is selected from: a combination of one or more of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii.
[0047] The present invention also provides an in vitro cell-free synthesis system, characterized in that the single-chain polypeptide is synthesized using mRNA or DNA encoding the single-chain polypeptide as a template.
[0048] The in vitro cell-free synthesis system provided by the present invention also has the following characteristics, including any one or more of the following:
[0049] (1) an mRNA or DNA template encoding the single-chain polypeptide;
[0050] (2) a cell extract, wherein the cell extract is a yeast cell extract, and further, the cell extract is derived from a strain of the following group: any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris, and Kluyveromyces; preferably, the yeast cell extract is derived from a strain of Kluyveromyces, more preferably Kluyveromyces lactis;
[0051] (3) Any one or more of the following components:
[0052] Amino acid mixture, dNTPs, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent.
[0053] The present invention also provides a method for preparing the aforementioned single-chain polypeptide, characterized in that:
[0054] The single-chain polypeptide is obtained by performing an in vitro synthesis reaction using the mRNA or DNA encoding the single-chain polypeptide as a template,
[0055] Preferably, the in vitro synthesis reaction is carried out in a reaction system comprising the aforementioned in vitro cell-free synthesis system.
[0056] Furthermore, the volume ratio of the DNA template to other components involved in the in vitro synthesis reaction ranges from 1:10 to 1:50, or from 1:20 to 1:40, or from 1:25 to 1:35, or from 1:30.
[0057] The preparation method provided by the present invention also has the following characteristics: wherein the cell-free in vitro synthesis system comprises: yeast cell extract, amino acid mixture, dNTP, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent;
[0058] Further:
[0059] The yeast cell extract is derived from the following strains: any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris, and Kluyveromyces; preferably, the yeast cell extract is derived from Kluyveromyces, more preferably Kluyveromyces lactis.
[0060] The preparation method provided by the present invention also has the following characteristics: wherein the yeast cell extract accounts for 50-80% of the volume of the entire cell-free in vitro protein synthesis system.
[0061] The preparation method provided by the present invention also has the following characteristics: it also includes: the obtained single-chain polypeptide including the second enzyme cleavage site is enzymatically digested with a second protease to obtain a single-chain polypeptide including only the first domain, the middle amino acid sequence region and the second domain.
[0062] The present invention also provides a use of the aforementioned nucleic acid, the aforementioned vector, the aforementioned host cell, or the aforementioned in vitro cell-free synthesis system in preparing the aforementioned single-chain polypeptide.
[0063] Functions and effects of the invention
[0064] The present invention provides a single-chain polypeptide that is activated upon use, specifically a single-chain polypeptide, its corresponding application, a nucleic acid encoding the same, and a preparation method thereof, which has at least the following advantages:
[0065] (1) The single-chain polypeptide provided by the present invention has a first enzyme cleavage site between the first domain and the second domain, which is designed to be highly specifically cleaved by a first protease present in a specific part of the human body. In this way, when the first enzyme cleavage site enters the specific use site, it is highly specifically cleaved by the first protease present in the specific part of the human body and converted into an activated form. Compared with the current method of being activated before leaving the factory, the safety of use is greatly improved. In particular, when used on skin tissue, due to its safety, it can be used safely and conveniently by applying or the like, thereby improving the usability, practicality and universality of the product.
[0066] (2) Furthermore, since the first protease does not exist in the human digestive tract, it will not be activated even if accidentally ingested, further improving the safety of use;
[0067] (3) Moreover, since the first enzyme cleavage site of the single-chain polypeptide is designed to be highly specifically cleaved by the first protease present in the specific part of the human body, and then the single-chain polypeptide is highly converted into an activated form, the production is safer, which not only ensures the safety of upstream production, but also ensures the safety of downstream product production. In particular, when the single-chain polypeptide of the present invention is synthesized in vitro using the mRNA or DNA encoding the single-chain polypeptide of the present invention as a template, some risks caused by leakage of the strain used in the intracellular expression synthesis method will not occur. In addition, the cycle is short, the method is simple, and the cost is low, which further improves safety and practicality. BRIEF DESCRIPTION OF THE DRAWINGS
[0068] FIG1 is an electrophoretic diagram of the modified protein obtained after elution and purification under pH 8.0 conditions in the embodiment;
[0069] Figure 2 is a reference diagram for scoring effects in animal experiments;
[0070] FIG3 is a diagram showing the animal experiment results of Example 7;
[0071] Figures 4 and 5 show the substrate conversion rates of different concentrations of substrates CFP-SNAP25(17aa)-YFP and CFP-SNAP25(66aa)-YFP, respectively, in Example 6;
[0072] FIG6 is a graph showing the comparison of the activity effects of TEV single-cleavage products and double-cleavage products in Example 6 to exclude the influence of TEV enzyme;
[0073] FIG7 is a graph showing the results of comparing the activity effects of the double-enzyme digestion product and the KLK5 enzyme in Example 6 to exclude the influence of the KLK5 enzyme;
[0074] FIG8 is an in vitro activity assay of single enzyme cleavage at multiple first enzyme cleavage sites in Example 6;
[0075] FIG9 is a graph showing the detection results of LD50 in Example 8;
[0076] FIG10 is a graph showing the ED50 detection results in Example 9. DETAILED DESCRIPTION
[0077] The specific embodiments of the present invention are described below with reference to the accompanying drawings. For the specific methods or materials used in the examples, those skilled in the art can make conventional replacements based on the technical ideas of the present invention and existing technologies, and are not limited to the specific description of the embodiments of the present invention.
[0078] Unless otherwise specified, the methods used in the examples are conventional methods; the materials, reagents, etc. used are all commercially available unless otherwise specified.
[0079] 1. Description of single-chain polypeptide
[0080] Signal transduction is the process of transmitting extracellular information into cells. It is a fundamental concept in cellular communication, emphasizing the generation, secretion, and transmission of signals—the release of informational substances from synthesized cells and their subsequent transmission. After a receptor recognizes and binds to its corresponding ligand (first messenger), intracellular levels of substances such as cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), calcium ions, and inositol phospholipids (second messengers) increase. These substances participate in various cellular biological regulatory processes, amplifying, differentiating, integrating, and transmitting the acquired information to effectors, thereby exerting specific physiological functions or pharmacological effects.
[0081] Information transduction between human cells can be achieved through direct contact between adjacent cells, but more importantly and more commonly, it is through the secretion of various chemical substances by cells to regulate their own and other cells' metabolism and function. Therefore, in the human body, the information conduction pathway is usually composed of specific cells that secrete and release information substances, information substances (including intercellular and intracellular information substances and carriers, transport pathways, etc.) and target cells (including specific receptors, etc.).
[0082] Information substances can be divided into intercellular information substances and intracellular information molecules.
[0083] All chemical substances secreted by cells that regulate the vital activities of target cells are collectively called intercellular messengers, i.e., first messengers. According to the way cells secrete messengers, intercellular messengers can be divided into neurotransmitters, endocrine hormones, local chemical mediators, and gaseous signal molecules. Chemical substances that transmit cell regulatory signals within cells are called intracellular messengers, and their composition is diverse. Usually, Ca 2+Small molecules that transmit information within cells, such as cAMP, cGMP, DAG, IP3, Cer, arachidonic acid, and its metabolites, are called second messengers. Substances responsible for transmitting information inside and outside the cell nucleus are called third messengers. They can bind to specific sequences in target genes and function as transcription factors or transcription regulators.
[0084] Neurotransmitters are substances that transmit information between neurons or between neurons and effector cells such as muscle cells and glandular cells. Based on their chemical composition, neurotransmitters mainly include choline (acetylcholine, Ach for short), monoamines (norepinephrine, dopamine, and serotonin), amino acids (excitatory transmitters such as glutamate and aspartic acid; inhibitory transmitters such as gamma-aminobutyric acid, glycine, and taurine), and neuropeptides.
[0085] The synthesis of acetylcholine (Ach) occurs primarily within cholinergic nerve endings. When a nerve impulse reaches the nerve ending, the vesicle membrane fuses with the presynaptic membrane, releasing acetylcholine into the synaptic cleft, stimulating the corresponding receptors on the postsynaptic membrane and triggering a series of physiological effects. Simultaneously, acetylcholine is hydrolyzed into choline and acetic acid by cholinesterase (ChE) in the nerve ending, inactivating it. Some choline is then taken up again by the cholinergic nerve endings and participates in the synthesis of new acetylcholine.
[0086] Existing studies have shown that by inhibiting the transmission of acetylcholine, it can lead to muscle relaxation, relieve muscle spasms, regulate hypertonia and movement disorders as well as dynamic wrinkles; in addition, it can also reduce muscle volume by causing muscle disuse atrophy to achieve body shaping.
[0087] Non-cytotoxic proteases act by proteolytically cleaving intracellular transport proteins called SNARE proteins (see Gerald K (2002) - Cell and Molecular Biology (4th edition) John Wiley & Sons, Inc.).
[0088] The acronym SNARE is derived from the term Soluble NSF Attachment Receptor, where NSF stands for N-ethylmaleimide-Sensitive Factor.
[0089] SNARE proteins are necessary for intracellular vesicle fusion and are therefore necessary for secretion of molecules from cells via vesicle transport. The non-cytotoxic protease function is a zinc-dependent endopeptidase activity and displays high substrate specificity for SNARE proteins. SNARE proteins are associated with the membrane or cell membrane of secretory vesicles and promote exocytosis of molecules by mediating the fusion of secretory vesicles with the cell membrane, thereby allowing the contents of the vesicles to be expelled from the cell. Cutting of neuronal SNAREs prevents the release of neurotransmitters, thereby leading to paralysis. Therefore, once the non-cytotoxic protease is delivered to the desired target cell, the non-cytotoxic protease is able to inhibit cellular secretion by the desired target cell.
[0090] The three proteins at the synaptic terminal, synaptobrevin VAMP on the synaptic vesicle membrane, syntaxin and SNAP-25 on the presynaptic membrane are all called SNARE proteins.
[0091] The single-chain polypeptide provided by the present invention comprises: a first structural domain, an intermediate amino acid sequence region, and a second structural domain.
[0092] The middle amino acid sequence region and the first domain can be separated by amino acids (linker, L1>0) or directly connected (L1=0). Similarly, the first cleavage site and the second domain can be separated by amino acids (linker, L2>0) or directly connected (L2=0).
[0093] In one example, the number of amino acids in the linker (L1) between the first domain and the middle amino acid sequence region is 0-20 or 0-10 amino acids or 0-5 amino acids.
[0094] In one example, the number of amino acids in the linker (L2) between the middle amino acid sequence region and the second domain is 0-20 or 0-10 amino acids or 0-5 amino acids.
[0095] The intermediate amino acid sequence region sequence contains at least one first enzyme cleavage site, and when there are multiple first enzyme cleavage sites:
[0096] These first enzyme cleavage sites may be identical, all identical, or different from each other;
[0097] A plurality of the first enzyme cleavage sites are sequentially connected from the N-terminus to the C-terminus;
[0098] The number of amino acids in the linker (L4) between the multiple enzyme cleavage sites is 0-20, 0-10, or 0-5.
[0099] The first enzyme cleavage site is designed to be highly specifically cleaved by a first protease in a specific part of the human body. After being cleaved by the first protease at the first enzyme cleavage site, the single-chain polypeptide is converted into an activated form. The activated form of the single-chain polypeptide can inhibit the release of the aforementioned information substance.
[0100] Specific parts of the human body, i.e., the parts where the single-chain polypeptide enters the human body when used in the human body, such as the digestive tract, skin tissue, cells, etc. When used, the specific parts of the human body can be entered in a variety of ways, for example, for skin tissue, it can be applied by smearing, external application, spraying, injection, etc.
[0101] The highly specific cleavage herein means that, under normal circumstances, the enzyme cleavage site is mainly recognized and cleaved by the corresponding specific protease and cannot be cleaved by other proteases. That is, under most conditions, the enzyme cleavage site and the corresponding protease have a unique correspondence.
[0102] Specifically, "the first enzyme cleavage site is designed to be highly specifically cleaved by a first protease present in a specific part of the human body where the single-chain polypeptide is used" means that the first enzyme cleavage site, under most conditions, has a unique correspondence with one or several first proteases present in a specific part of the human body. For example, when the site of use is the digestive tract, it has a unique correspondence with one or several proteases present in the digestive tract. For another example, when the site of use is skin tissue, it has a unique correspondence with one or several proteases present in the skin tissue.
[0103] In this way, the single-chain polypeptide is only used in a specific part of the human body where the aforementioned first protease exists, for example, applied to the skin surface and enters the skin tissue, through the enzymatic cleavage of the first enzyme cleavage site by the first protease present in the skin tissue that is highly specific to the first enzyme cleavage site, so that the single-chain polypeptide is converted into an activated form that can inhibit the release of information substance.
[0104] The activated form of the single-chain polypeptide is a double-chain structure in which the first and second domains are connected by a disulfide bond. In the activated form, the disulfide bond is reduced, thereby producing a product with cleavage activity, thereby inhibiting the release of signaling substances such as neurotransmitters. The cleavage activity referred to herein refers to cleavage of proteins associated with vesicles and / or plasma membranes involved in cell exocytosis:
[0105] Essentially, the first and second domains are separated by this intermediate amino acid sequence region, and this intermediate amino acid sequence region contains a first enzyme cleavage site, but does not contain a non-wild-type cleavage amino acid sequence, that is, a non-naturally occurring cleavage amino acid sequence between the first and second domains (a wild-type cleavage amino acid sequence or a naturally occurring cleavage amino acid sequence refers to a naturally occurring single-chain polypeptide that can convert the first and second domains from a single-chain to a double-chain active structure through cleavage of this naturally occurring cleavage amino acid sequence). This is equivalent to replacing the function of the wild-type cleavage amino acid sequence with the first enzyme cleavage site, enabling cleavage only under the highly specific action of the first protease. For example, when the first domain is the light chain of botulinum toxin type A and the second domain is the light chain of botulinum toxin type A, the intermediate amino acid sequence region does not contain the "KTKSLDKGYNK" sequence, which is naturally cleaved by the enzyme (the natural cleavage site sequence).
[0106] In one example, the information substance is acetylcholine.
[0107] Experiments have shown that the activated form of the single-chain polypeptide, that is, the aforementioned double-chain structure, can have a relaxing effect on muscles, for example, that is, it has the function of inhibiting the transmission of information substances such as neurotransmitters.
[0108] Preferably, the first domain, the first enzyme cleavage site and the respective parts of the second domain are connected from N-terminus to C-terminus.
[0109] In one example, the first domain has a molecular weight of approximately 50 kDa, and the second domain has a molecular weight of approximately 100 kDa.
[0110] In a specific example, the single-chain polypeptide designed by the present invention has a first domain that is a non-toxic cellular protease or a fragment thereof that can cut the protein of the exocytosis fusion apparatus of the target cell. In one example, the cell is a neuronal cell, the protein of the exocytosis fusion apparatus is the neuronal snare protein, and / or the target binding site is a receptor on the presynaptic membrane of the neuron.
[0111] When the protein of the exocytotic fusion apparatus is the SNARE protein of a neuronal cell, the physiological function of cholinergic nerve conduction is blocked by cutting the SNARE protein, for example, preventing the release of the acetylcholine neurotransmitter.
[0112] In one example, the SNARE protein is selected from the group consisting of: VAMP, syntaxin, and SNAP-25.
[0113] The second domain has a binding portion and a transport portion:
[0114] The binding moiety can bind to a target cell receptor and be taken up into the endosome of the target cell through receptor-mediated endocytosis, for example, binding to ectoacceptors on the presynaptic membrane of nerve terminals.
[0115] Transport The transport moiety is capable of transporting the first domain into the cytosol of the target cell.
[0116] The binding part of the second domain binds to the target cell receptor and is received in the endosome of the target cell through receptor-mediated endocytosis. The transport part brings the first domain into the cytosol of the target cell. In the cytosol, the second domain is cut off by reducing the disulfide bond, and the first domain is released into the cytosol, thereby cutting the SNARE protein and inhibiting the release of neurotransmitters, thereby causing muscle relaxation and relieving muscle spasms, thereby regulating hypertonia, movement disorders and dynamic wrinkles; and achieving muscle disuse atrophy and reducing muscle volume for body shaping.
[0117] The binding portion is carboxyl-terminal and has a molecular weight of approximately 50 kD, and the transport portion is amino-terminal and has a molecular weight of approximately 50 kD.
[0118] In one example, the first domain comprises at least a portion of a Clostridium neurotoxin L chain, preferably the portion of the Clostridium neurotoxin L chain is a neurotoxin L chain of one of Clostridium botulinum subtypes A, B, C, D, and E or is derived therefrom; and / or,
[0119] The first domain comprises an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to SEQ ID NO: 10, or an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of 11-16, with the naturally occurring enzyme cleavage sequence removed;
[0120] In one example, the second domain includes at least a portion of the Clostridium neurotoxin H chain:
[0121] Preferably, the partial clostridial neurotoxin H chain is a neurotoxin heavy chain of one of the following: Clostridium botulinum subtype A, Clostridium botulinum subtype B, Clostridium botulinum subtype C, Clostridium botulinum subtype D, Clostridium botulinum subtype E, Clostridium botulinum subtype F, Clostridium botulinum subtype G, Clostridium pasteurian (C. Baratii) and Clostridium butyricum (C. Butyricum); or the partial clostridial neurotoxin H chain is a neurotoxin H chain of Clostridium tetani (C. Tetani) or is derived therefrom; and / or
[0122] The second domain comprises an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 17-23.
[0123] Furthermore, the first protease is not a protease present in the human digestive tract, that is, there is no protease in the human digestive tract that can highly specifically cut the first enzyme cleavage site, or in other words, under most normal conditions, the first enzyme cleavage site cannot be cut by the protease present in the human digestive tract. In this way, the problem of poisoning caused by accidental ingestion into the digestive tract during use is avoided, thereby ensuring safe use.
[0124] The digestive tract mentioned in this article refers to the very long muscular tube that extends from the mouth to the pharynx, esophagus, stomach, small intestine, large intestine, and finally to the anal canal, including the mouth, pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine (cecum, appendix, colon, rectum) and anal canal.
[0125] In one example, the specific part of the human body is human skin tissue, that is, the first protease exists in the human skin tissue.
[0126] The term "skin tissue" used herein refers to the entire "skin" of the body, including the scalp and mucous membranes. The epidermis is the outermost layer of the skin, which covers the entire body and provides protection.
[0127] The layers of skin tissue can be divided into three parts: epidermis, dermis, and subcutaneous tissue:
[0128] (1) Epidermis
[0129] The epidermis is the outermost layer of the skin, covering the entire body and providing protection. While it lacks blood vessels (thus preventing bleeding after a scratch), it contains numerous tiny nerve endings. Based on cell morphology, the epidermis can be divided into five layers: stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum, and stratum basale.
[0130] 1. Stratum corneum
[0131] The stratum corneum is the outermost layer of the epidermis, composed of 4 to 8 thin, flat layers of dead keratinized cells stacked together.
[0132] 2. Transparent layer
[0133] The clear layer is composed of 2-3 layers of flat, anucleated, transparent keratinized cells.
[0134] 3. Granular layer
[0135] The granular layer is composed of 2-5 thick layers of flattened cells. These cells are characterized by their inability to divide and near-death, with transparent keratin granules visible within them. This layer refracts light, reducing the amount of ultraviolet light that enters the body.
[0136] 4. Spinous cell layer
[0137] The spinous layer, composed of 4-10 layers of polygonal cells with spines, is the thickest layer of the epidermis. Spaces exist between the cells of this layer. Glucosaminoglycans are present between the cells. These hydrophilic sugars facilitate the exchange of substances with the surrounding environment. Granular phospholipids and acidic mucopolysaccharides are also present within the cytoplasm, serving as a site for lymphatic circulation and substance exchange. It also contains numerous sensory nerve endings, tissue fluid that senses various external stimuli, and provides nutrients to cells.
[0138] 5. Basal layer
[0139] The basal cell layer is the innermost layer of the epidermis, connecting to the dermis in a wavy pattern. It is composed of 2-4 layers of cells of different shapes. This layer is the proliferative part of the epidermis. After proliferation, new cells move toward the outer layers and gradually differentiate into cells in the other layers.
[0140] (2) Genuine leather
[0141] The cellular components of the dermis include fibroblasts, macrophages, and mast cells [2]. Collagen fibers, elastic fibers, and matrix are all secreted by fibroblasts. Reticular fibers are immature collagen fibers and are not an independent component. The thickness of the dermis is closely related to the amount of fibrous tissue and matrix, and is closely related to the density, plumpness, laxity, and wrinkling of the skin. In recent years, it has attracted the attention of more and more cosmetic skin scientists.
[0142] 1. Collagen fibers are the most abundant component of dermal connective tissue. Below the epidermis, collagen fibers near epidermal appendages and blood vessels are small and irregular in orientation. Elsewhere in the dermis, collagen fibers are bound together into bundles. They become thinner toward the upper dermis and thicker toward the lower dermis. In the middle and lower dermis, collagen bundles run nearly parallel to the skin surface and intertwine, extending in various directions on a horizontal plane. Collagen fibers are considered the dermal component most closely associated with skin aging.
[0143] 2. Reticular fibers can be considered newly formed, delicate collagen fibers. They first appear during the embryonic period. In normal adult skin, reticular fibers are scarce, found only beneath the epidermis and around sweat glands, sebaceous glands, hair follicles, and capillaries. Subepidermal reticular fibers are arranged in a web-like pattern. Reticular fibers also surround each fat cell. Reticular fibers can proliferate significantly during wound healing or in conditions where fibroblasts are actively proliferating, leading to new collagen formation.
[0144] 3. Elastic fibers are much thinner than collagen fibers and have a wavy appearance. They are thickest in the dermis and align in the same direction as collagen bundles, becoming entangled between them and oriented parallel to the epidermis. Within the papillary bodies beneath the epidermis, tiny elastic fibers rise almost vertically beneath the epidermis, terminating just below the epidermal-dermal junction. Elastic fibers are closely associated with skin elasticity.
[0145] 4. The matrix is an amorphous substance that fills the spaces between collagen fibers and collagen bundles. The matrix in the normal dermis primarily contains non-sulfate acidic mucopolysaccharides, such as hyaluronic acid. Although present in very low amounts in normal skin, it can absorb 1,000 times its own water content, making it crucial for anti-wrinkle and anti-aging efforts.
[0146] 5. Cells: The dermis contains fibroblasts, mast cells, histiocytes, lymphocytes, and a small number of true dermal fasciculi, melanophages, and Langerhans cells. Fibroblasts produce collagen fibers, elastic fibers, reticular fibers, and matrix. They are also the primary cells responsible for tissue repair following deep skin damage.
[0147] (3) Subcutaneous tissue
[0148] Subcutaneous tissue is the loose connective tissue and fat tissue beneath the skin, connecting the skin to the muscles and often referred to as superficial fascia. It lies between the skin and deeper tissues, allowing the skin to have a certain degree of mobility.
[0149] The subcutaneous tissue is composed of loose connective tissue and fat lobules, which are connected to the dermis above and to the fascia, muscular aponeurosis, or periosteum below. Fat cells have transparent cytoplasm, and the nucleus is located at the inner edge of the cell. Fat cells aggregate to form primary lobules, which in turn form secondary lobules. These secondary lobules are surrounded by fibrous septa, or trabeculae. These fat septa contain blood vessels, lymphatic vessels, nerves, and eccrine and apocrine sweat glands.
[0150] In one example, the first protease is selected from any one or more of the following:
[0151] Epidermal-specific kallikreins (KLKs, human kallikrein-related peptidases) (e.g., KLK5, KLK6, KLK7), SASPase, Caspase-14, Furin protease.
[0152] Epidermal-specific kallikreins (KLKs) belong to a family of serine proteases that are expressed in the stratum granulosum. KLKS is a secreted trypsin-like serine protease that appears to be most abundantly expressed in human skin, particularly in the upper stratum spinosum and stratum granulosum, where keratinocytes undergo terminal differentiation and transform into flat, brick-like structures that form the stratum corneum, the outermost epidermal layer and the barrier to the external environment [1].
[0153] [1] Debela et al., J Mol Biol, 373, 1017-1031 (2007); and Tan et al., J Med Chem. 2015 Jan 22;58(2):598-612 (2014).
[0154] KLKs are encoded by 15 different genes, each containing 5 exons and arranged in tandem on human chromosome 19. The 15 human KLK genes are located on chromosome 19q13.4, forming the largest continuous cluster of serine proteases in the human genome. These genes typically consist of five coding exons and, in some cases, one or two 5' non-coding exons, encoding the kallikrein-related peptidases KLK1 to KLK15. All KLK genes encode single-chain preproproteins containing a chymotrypsin or trypsin-like catalytic domain of 224-237 residues [2].
[0155] [2] Debela et al., Biol Chem 389, 623-632 (2008).
[0156] Of the 15 members of the KLK family, 11 are expressed in the skin, with their range being limited to the epidermis and skin appendages. Gene expression analysis showed that KLK1 and KLK11 are the most highly expressed KLKs in the skin. KLK4, KLK5, KLK6, KLK7, and KLK13 are moderately expressed, while KLK8 mRNA is rarely detected under steady-state conditions [3]. In terms of expression location, the mRNAs of KLK6, KLK9, KLK10, KLK13, and KLK14 appear to be strictly restricted to the granular layer of the healthy epidermis, while the mRNAs of KLK1, KLK4, and KLK11 are present in both the spinous layer and the basal layer of keratinocytes.
[0157] Most KLK genes expressed in the epidermis are also expressed in the skin appendages [3]. At the protein level, KLKs are generally more widely distributed in the epidermis. KLK5 is present in the stratum granulosum and stratum corneum, while KLK6 is present throughout the epidermis but is only partially enriched in the stratum granulosum. KLK7 is detected in both the basal and supragranular layers of the epidermis but is barely detectable in the areas between them.
[0158] [3]N.Komatsu,M.Takata,N.Otsuki,T.Toyama,R.Ohka,K.Takehara,K.Saijoh,Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages, J. Invest. Dermatol. 121 (2003) 542–549. https: / / doi.org / 10.1046 / j.1523-1747.2003.12363.x.
[0159] In addition, KLK8 and KLK13 have been observed in the stratum corneum and stratum granulosum, as well as in the appendages of healthy skin [4, 5]. Thus, the distribution of protein is broader than that of gene expression, indicating that KLKs are diffuse in the epidermis. Of all KLKs, KLK14 appears to be the most skin-specific, with low levels in other tissues but relatively high levels in the skin, at 250 ng / g of total protein [6, 7].
[0160] [4]N.Komatsu,K.Saijoh,T.Toyama,R.Ohka,N.Otsuki,G.Hussack,K.Takehara,EPDiamandis,Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases,Br.J.Dermatol.153(2005)274–281.https: / / doi.org / 10.1111 / j.1365-2133.2005.06754.x.
[0161] [5]M.Kishibe,Y.Bando,R.Terayama,K.Namikawa,H.Takahashi,Y.Hashimoto,A.Ishida-Yamamoto,Y.Jiang,B.Mitrovic,D.Perez,H.Iizuka,S.Yoshida,Kallikrein 8 is involved in skin desquamation in cooperation with other kallikreins, J. Biol. Chem. 282 (2007) 5834–5841. https: / / doi.org / 10.1074 / jbc.M607998200.
[0162] [6]JLVShaw,EPDiamandis,Distribution of 15 human kallikreins in tissues and biological fluids,Clin.Chem.53(2007)1423–1432.https: / / doi.org / 10.1373 / clinchem.2007.088104.
[0163] [7]CA IPMichael,JLVShaw,L.Luo,MCGhosh,A.Soosaipillai,L.Grass,D.Katsaros,EPDiamandis,Expression and functional characterization of the cancerrelated serine protease,human tissue kallikrein 14, J. Biol. Chem. 282(2007)2405–2422. https: / / doi.org / 10.1074 / jbc.M608348200.
[0164] SASPase is a protease found in human skin with a molecular weight of 28 kDa. SASPase is specifically expressed in the stratum granulosum of human skin and produces a 14 kDa protein through autolysis. Recombinant SASPase has been reported to exhibit autolytic activity and degrade exogenous substrates such as insulin and casein. However, its function in the epidermis has not been determined [8].
[0165] [8] Bernard D. et al., J. Invest. Dermatol. 125, 278-287, 2005
[0166] The caspase family belongs to the cysteine protease family, equivalent to ced-3 in nematodes, and shares a high degree of homology. These proteases share the following characteristics: ① They always cleave substrates after aspartate, hence the name caspase (cysteine aspartate-specific protease). ② Enzyme activity depends on the nucleophilicity of the cysteine residue. ③ They typically exist as zymogens, consisting of two large and two small subunits. The large and small subunits are encoded by the same gene, and upon activation, the precursor is cleaved to produce two active subunits. These proteases are key enzymes in inducing apoptosis. Once the signal transduction pathway is activated, caspases are activated, followed by a cascade of apoptotic proteases. Activated enzymes within the cell degrade important proteins, ultimately leading to irreversible cell apoptosis.
[0167] Caspase-14 (CASP14) is a member of the caspase family and plays a key role in the formation and regulation of the skin stratum corneum.
[0168] Furin is an intracellular protease that proteolytically activates a large number of preprotein substrates in secretory pathway compartments by cleaving a cluster of basic residues, typically in the form of RX(K / R)R.
[0169] In one example, the first enzyme cleavage site comprises an amino acid sequence that is at least 50%, 60%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 1-4, SEQ ID NO: 50 (RXXR) and SEQ ID NO: 51 (RRXX).
[0170] In SEQ ID NO: 5049 and SEQ ID NO: 51, "X" in RXXR and RRXX is any amino acid. Preferably, "XX" in RXXR is RK, TK, or TR; and "XX" in RRXX is SV or KR.
[0171] In one example, the single-chain polypeptide provided by the present invention is characterized in that it further comprises: one or more of a signal peptide for increasing expression level, a quantitative protein for quantification, and a tag protein.
[0172] Furthermore, one or more of the signal peptide, quantitative protein, and tag protein are defined as follows:
[0173] The signal peptide comprises an amino acid sequence that is at least 85%, 90%, 99% or 100% identical to SEQ ID NO: 24;
[0174] The quantitative protein is a fluorescent protein;
[0175] The tag protein is one or more of a His tag, a GST tag, an MBP tag, and a Strep-tag II tag, or contains an amino acid sequence that is at least 85%, 90%, 99% or 100% identical to SEQ ID NO: 25.
[0176] "The following corresponding limitations are made on one or more of the signal peptide, quantitative protein and tag protein respectively", for example, only the corresponding limitations are made on the signal peptide among the signal peptide, quantitative protein and tag protein, or the corresponding limitations are made on the signal peptide, quantitative protein and tag protein respectively, or any two of the signal peptide, quantitative protein and tag protein respectively, etc.
[0177] In one example, the single-chain polypeptide further includes: two second enzyme cleavage sites located at the N-terminus of the first structure and the C-terminus of the second structure, respectively, and the second protease that cleaves the second enzyme cleavage site cannot cleave the first enzyme cleavage site. In this way, by enzymatic cleavage of the two second enzyme cleavage sites, the first domain, the first enzyme cleavage site and other parts other than the second domain in the single-chain polypeptide can be cut and removed, for example, the signal peptide, quantitative protein, tag protein, etc. can be removed to obtain a single-chain polypeptide with only the first domain, the first enzyme cleavage site and the second domain remaining.
[0178] In one example, the first enzyme cleavage site and / or the second enzyme cleavage site will not usually be cleaved by proteases encountered during the synthesis of a single-chain polypeptide by expressing the single-chain polypeptide in a host cell in vivo or by an in vitro synthesis system involving cell extracts from host cells. That is, when the single-chain polypeptide is obtained by expressing the single-chain polypeptide in a host cell in vivo or by synthesizing the single-chain polypeptide by in vitro synthesis involving host cell extracts, the first enzyme cleavage site and / or the second enzyme cleavage site will not usually be cleaved by proteases encountered in these two methods. In this way, when the first cleavage site meets this prerequisite, it will not be easily activated during production, thereby ensuring a certain level of production safety. When the second enzyme cleavage site meets this prerequisite, it can maintain a certain structure of the single-chain polypeptide as needed. For example, in the process of producing the single-chain polypeptide, the product can be easily purified during production due to the presence of a tagged protein.
[0179] In one example, the second enzyme cleavage site is designed to be highly specific to the second protease, that is, as mentioned above, the second enzyme cleavage site has a unique correspondence with the second protease, so that the second enzyme cleavage site can only be cleaved by the specific second protease under most normal circumstances (that is, under normal circumstances), and will not be arbitrarily cleaved during production, so that the single-chain polypeptide maintains a certain structure before the second enzyme cleavage site is cleaved.
[0180] Furthermore, the second protease is not a commonly occurring enzyme, for example, not a protease in the human body. The protease in the human body herein refers to a protease that is not commonly occurring in the human body. This reduces, for example, cleavage by contact with a protease in the human body during production, which may change the structure at an inappropriate time.
[0181] In one example, preferably, the second protease is selected from non-human enterokinase, tobacco etch virus protease, a protease derived from Bacillus subtilus, a protease derived from Bacillus amyliquifaciens, a protease derived from rhinovirus, papain, a homolog of insect papain, or a homolog of crustacean papain.
[0182] In one example, the second restriction enzyme cleavage site comprises an amino acid sequence that is at least 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 5 to 9. In SEQ ID NO: 6: EXXYXQS / G, X represents any amino acid.
[0183] In one example, when the second domain comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 17, the lysine at position 423 of the amino acid sequence of the second domain corresponding to SEQ ID NO: 17 is mutated to a non-lysine. For example, the lysine is mutated to asparagine, glutamic acid, or alanine, thereby preventing the second domain from being cleaved by trypsin and losing its activity.
[0184] The lysine at position 423 herein, for an amino acid sequence that is completely identical (i.e., 100% identical) to SEQ ID NO: 17, refers to the lysine at position 423. For other amino acid sequences that do not contain completely identical to SEQ ID NO: 17, it refers to the position number of the lysine at position 423 in the amino acid sequence at that time that is within a reasonable misalignment range with the position number of position 423 of SEQ ID NO: 17. The reasonable misalignment range here refers to the fact that, for those skilled in the art, when the identity of the amino acid sequence, that is, the homology with the amino acid sequence used for comparison reaches 80% or more, there will be a certain misalignment of the position number toward the N-terminus or C-terminus compared with the amino acid sequence used for comparison, and such misalignment is acceptable.
[0185] For example, compared with the sequence of SEQ ID NO: 17, an amino acid sequence that has at least 80% identity with SEQ ID NO: 17 has an amino acid lysine at position 423 when the position is misaligned by 5 positions compared with SEQ ID NO: 17. This error range of 5 positions is within an acceptable range, so those skilled in the art can assume that the position number 427 of this position is the lysine corresponding to the 423rd position.
[0186] In one example, the middle amino acid sequence region sequence further includes XTXS, wherein X is not a K amino acid, preferably, X is a Q amino acid.
[0187] In a preferred example, the structure of the intermediate amino acid sequence region from N-terminus to C-terminus is:
[0188] XTXS-linker (L3) - at least one first enzyme cleavage site: Similarly, when there are multiple first enzyme cleavage sites, all of the first enzyme cleavage sites have the same cleavage site or are different from each other. Preferably, the multiple first enzyme cleavage sites are linked sequentially from the N-terminus to the C-terminus. Furthermore, the number of amino acids in L3 is 0-20, 0-10, or 0-5.
[0189] There is no particular limitation on the connection between the first domain, the middle amino acid sequence region (when the middle amino acid sequence region only has the first enzyme cleavage site), and the second domain herein. Preferably, the connection is from the N-terminus to the C-terminus.
[0190] 2. Application
[0191] The aforementioned single-chain polypeptide provided by the present invention is used in any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms.
[0192] Specifically, the present invention also provides a single-chain polypeptide product or medicine, which includes: the aforementioned single-chain polypeptide. Preferably, the single-chain polypeptide product is used for any one or more of the following purposes: skin care, plastic surgery, body shaping, and treatment by causing muscle relaxation and relieving muscle spasms.
[0193] In addition, when used, the above-mentioned single-chain polypeptide products or drugs can enter a specific part through methods such as smearing, spraying, external application or injection, for example, by smearing into the skin tissue. After entering, they are cleaved by a specific first protease at the first cleavage site in the specific part, and the single-chain polypeptide is converted into an activated form, thereby exerting its effect.
[0194] 3. The present invention also provides a nucleic acid comprising: a nucleotide sequence encoding the aforementioned single-chain polypeptide.
[0195] The present invention also provides a vector comprising the above nucleic acid.
[0196] The present invention also provides a host cell comprising the aforementioned nucleic acid and / or the aforementioned vector, wherein the host cell is derived from a prokaryotic cell or a eukaryotic cell, and further, the cell is selected from the group consisting of one or more combinations of Escherichia coli cells, human cells, Chinese hamster cells, ovary cells, insect cells, wheat germ cells, rabbit reticulocytes, and yeast cells.
[0197] Furthermore, the host cell is selected from yeast cells, and further still, the yeast cell is selected from: a combination of one or more of Saccharomyces cerevisiae and Kluyveromyces yeast. In another preferred embodiment, the Kluyveromyces yeast is selected from: a combination of one or more of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii.
[0198] The present invention also provides an in vitro cell-free synthesis system, comprising: synthesizing the single-chain polypeptide using an mRNA or DNA template encoding the single-chain polypeptide.
[0199] In one example, the in vitro cell-free synthesis system includes any one or more of the following:
[0200] (1) an mRNA or DNA template encoding the aforementioned single-chain polypeptide;
[0201] (2) Cell extract, wherein the cell extract is a yeast cell extract:
[0202] In one example, the cell extract is derived from the following strains: any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris, and Kluyveromyces; preferably, the yeast cell extract is derived from Kluyveromyces, more preferably Kluyveromyces lactis;
[0203] (3) Any one or more of the following components:
[0204] Amino acid mixture, dNTPs, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent.
[0205] 4. Preparation method of single-chain polypeptide:
[0206] In vitro synthesis of the single-chain polypeptide is carried out using mRNA or DNA template encoding the above-mentioned single-chain polypeptide.
[0207] Deserve.
[0208] In one example, the in vitro synthesis reaction is carried out in a reaction system including the aforementioned in vitro cell-free synthesis system. Preferably, the volume ratio of the DNA template to other components involved in the in vitro synthesis reaction is in the range of 1:10-1:50 or 1:20-1:40 or 1:25-1:35 or 1:30.
[0209] In one example, the cell-free in vitro synthesis system includes: yeast cell extract, amino acid mixture, dNTP, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol, and aqueous solvent.
[0210] In one example, the yeast cell extract is from the group consisting of any one or more of Saccharomyces cerevisiae, Pichia pastoris, and Kluyveromyces; preferably, the yeast cell extract is from Kluyveromyces, more preferably Kluyveromyces lactis.
[0211] In one example, yeast extract accounts for 50-80% of the volume of the entire cell-free in vitro synthesis system.
[0212] The present invention expresses and purifies the aforementioned single-chain polypeptide through the aforementioned in vitro synthesis reaction, which has a short cycle and is easy to operate. Moreover, because an in vitro preparation method using an mRNA or DNA template is used, a DNA template for a plasmid-modified gene can be used, and there is no risk of leakage of toxic strains.
[0213] In one example, the method for preparing the single-chain polypeptide further includes: enzymatically digesting the obtained single-chain polypeptide or the purified single-chain polypeptide with a second protease to obtain a single-chain polypeptide comprising only the first domain, the first enzyme cleavage site, and the second domain.
[0214] The cell-free in vitro synthesis system of the present invention includes an in vitro translation system, an in vitro transcription and translation system (IVTT system), and the like.
[0215] In vitro protein synthesis reaction refers to a reaction for synthesizing protein in an in vitro cell-free synthesis system, including at least a translation process. Including but not limited to IVTT reaction (in vitro transcription and translation reaction). In the present invention, IVTT reaction is preferred. IVTT reaction, corresponding to IVTT system, is the process of transcribing and translating DNA into protein (Protein) in vitro. Therefore, we also refer to this type of in vitro protein synthesis system as D2P system, D-to-P system, D_to_P system, DNAto-Protein system; the corresponding in vitro protein preparation method is also called D2P method, D-to-P method, D_to_P method, DNA-to-Protein method.
[0216] In the in vitro synthesis reaction of the embodiments of the present invention, the cell-free in vitro synthesis system, template, plasmid, target protein, in vitro synthesis reaction (incubation reaction), various preparation methods, various detection methods and other technical elements can also be independently selected from the following documents. Suitable implementation methods or implementation methods include but are not limited to CN111484998A, CN106978349A, CN108535489A, CN108690139A, CN108949801 A, CN108642076A, CN109022478A, CN109423496A, CN109423497A, CN109423509A, CN109837293A, CN109971783A, CN109988801A, CN109971775A, CN110093284A, CN110408635A, CN110408636A, CN110551745A, CN110551700A, CN110551785A, CN110819647A, CN110845622A, CN110938649A, CN110964736A and other documents. Unless otherwise inconsistent with the purpose of the present invention, these documents and the documents cited are cited in their entirety and for all purposes.
[0217] The present invention is further described below based on the source of botulinum toxin type A and in combination with various experimental examples.
[0218] Example 1 DNA template preparation
[0219] 1. Construction of target plasmid:
[0220] (1) Constructing a target plasmid containing a nucleotide sequence encoding a protein structure as shown in Formula 1:
[0221] SP-8His-F2-LC-D(KTKS-F1)-HC-F2-EGFP-8His (Formula 1, N-terminus to C-terminus linkage);
[0222] Wherein, D represents the middle amino acid sequence region, KTKS is part of the natural type A botulinum toxin cleavage site, and F1 represents the first enzyme cleavage site designed by the present invention, corresponding to several different first proteases, KLK5, KLK7, SASPase, and Caspase-14, respectively;
[0223] F2 is the second enzyme cleavage site, corresponding to the second protease. In this embodiment, the second protease is TEV enzyme;
[0224] SP is a signal peptide, 8His is a tag protein; EGFP is a fluorescent protein, used for quantification;
[0225] LC is the first domain. In this embodiment, the amino acid sequence of LC is SEQ ID NO: 10. HC is the second domain. In this embodiment, the amino acid sequence of HC is SEQ ID NO: 17.
[0226] Lysine 423 of HC was mutated to asparagine.
[0227] The primers in Table 1 correspond to the nucleotide sequences encoding the above protein structures corresponding to different first proteases;
[0228] According to each primer pair in Table 1, the correct sequence was obtained by the QuickChange PCR method, and different target plasmids were obtained by transformation.
[0229] (2) For the protein structure of the above structural formula 1, the original natural botulinum toxin A was modified by mutating the 438th and 440th lysines into alanines starting from LC, and the corresponding modified target plasmid was constructed, that is, the middle amino acid sequence region D was QTQS-F1.
[0230] The primers in Table 2 are respectively modified to encode the nucleotide sequences of the modified protein structures corresponding to different first proteases.
[0231] The correct sequence was obtained by the QuickChange PCR method and transformed into different target plasmids.
[0232] (3) Plasmid transformation
[0233] Transformation of each target plasmid was performed as follows:
[0234] Add 1 μl of target plasmid to 20 μl of DH5α, place on ice for 30 minutes, heat shock at 42°C for 45 seconds, place on ice for 2 minutes, add 500 μl of culture medium, and culture at 37°C with shaking (200 rpm) for 1 hour. Pipette 100 μl onto an LB plate (containing antibody), incubate upside down at 37°C for 12-16 hours, and then store in a refrigerator at 4°C.
[0235] (4) Extract and amplify the transformed plasmid:
[0236] Amplification system: random primers at a final concentration of 20-30 μM, 0.05-0.15 μg / mL plasmid template, 0.5-1 mM dNTPs, 2× BSA, 1× phi29 reaction buffer (50 mM Tris-HCl, 10 mM MgCl2, 10 mM (NH4)2SO4, 4 mM DTT, pH 7.5);
[0237] Take 10ml amplification system as an example:
[0238] Mix 10 ml of the amplification system, a plasmid with a final concentration of 4 ng / μl, and 5 μl of 0.05-0.1 mg / mL phi29 DNA polymerase, react at 37°C and 30 rpm for 2 hours, and then identify by electrophoresis using 1% agarose gel.
[0239] Example 2, In vitro cell-free protein synthesis (IVTT)
[0240] In vitro cell-free protein synthesis system: 22 mM 4-hydroxyethylpiperazineethanesulfonic acid (pH 7.4) at a final concentration, 30-150 mM potassium acetate, 1.0-5.0 mM magnesium acetate, 1.5-4 mM nucleoside triphosphate mixture (adenosine triphosphate, guanosine triphosphate, cytosine triphosphate, and uridine triphosphate), 0.08-0.24 mM amino acid mixture (glycine, alanine, valine, leucine, isoleucine, phenylalanine, proline, tryptophan, serine, tyrosine, cysteine, methionine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, and histidine), 25 mM creatine phosphate, 1.7 mM dithiothreitol, 0.27 mg / mL creatine phosphokinase, 0.027-0.054 mg / mL T7 RNA polymerase, 1%-4% polyethylene glycol, 0.5%-2% sucrose, and finally 50-80% volume of yeast cell extract are added.
[0241] The yeast cell extract of this example is from Kluyveromyces lactis.
[0242] More specifically, the IVTT reaction was performed using the Standard product from the protein factory of Kangma (Shanghai) Biotechnology Co., Ltd.:
[0243] The amplified product (DNA template) obtained in Example 1 was added to the cell-free in vitro protein synthesis system at a volume ratio of 1:30 to the in vitro cell-free protein system, and reacted in an incubator at 30±2 degrees and 100 rpm for 3 to 6 hours.
[0244] Example 3: Purification of in vitro synthesized protein: Purification was performed according to the following steps:
[0245] (1) Determine the amount of magnetic beads: The amount of magnetic beads is 1% of the amount used in the in vitro cell-free protein synthesis system.
[0246] (2) Magnetic bead cleaning: Wash with water three times before use, vortex for 15 seconds each time, and collect the magnetic beads using a magnetic rack. The amount of water used each time should be 5-10 times the amount of magnetic beads.
[0247] (3) Binding of target protein to magnetic beads: Mix the washed magnetic beads and IVTT product in a large beaker, combine at 4°C, 100 rpm for 1 hour, and collect the magnetic beads into a centrifuge tube.
[0248] (4) Washing: Wash the protein-loaded magnetic beads with 30 mM imidazole three times at 180 rpm for 10 minutes each time. The amount of washing solution used should be 3-5 times the volume of the magnetic beads.
[0249] (5) Elute with 280 mM imidazole eluent: the amount of eluent used is twice the amount of magnetic beads used.
[0250] (6) Centrifugation: Centrifuge to remove residual magnetic beads, first time for 5 minutes, 12000 rpm:
[0251] Among them, (4)-(5) were eluted at pH 8.0.
[0252] Example 4: Electrophoresis of the purification results
[0253] The electrophoresis results of the modified protein in which the first protease is KLK5 are shown in FIG1 .
[0254] In Figure 1, "+" indicates the corresponding action was performed, and "-" indicates the absence of the corresponding action. A disulfide bond reducing agent can reduce disulfide bonds. After the disulfide bond between the first and second domains of the activated single-chain polypeptide is reduced, the first and second domains are separated into two parts, 50 kDa and 100 kDa, respectively. Successful disulfide bond reduction indicates that a single-chain polypeptide protein capable of activation has been synthesized in vitro.
[0255] As can be seen from Figure 1, after the modification, that is, the 438th and 440th lysines of LC were mutated into alanines (the middle amino acid sequence region is (QTQS-F1)):
[0256] The corresponding protein can be obtained by purification at pH 8.0. Before enzyme digestion, even with the use of a disulfide bond reducing agent, the size is greater than 150 kDa, indicating that the corresponding protein has been obtained and that activation will not occur when the first enzyme cleavage site is not digested.
[0257] When only the second enzyme cleavage site is cleaved and the disulfide bond is reduced, the size obtained is close to 150 kDa, indicating that the second enzyme cleavage site is successfully cleaved, and only the first domain, the first enzyme cleavage site, and the second domain remain. When the first enzyme cleavage site is not cleaved, no activation will occur.
[0258] Both the first enzyme cleavage site and the second enzyme cleavage site were cleaved and reduced with a disulfide bond reducing agent at the same time, resulting in sizes of 100 kDa and 50 kDa. This comparison shows that after the first enzyme cleavage site is cleaved, it can indeed be converted into an activated form of a double-chain structure in which the first domain and the second domain are connected by a disulfide bond.
[0259] Before the modification, no electrophoretic pattern of purified protein was obtained after elution, indicating that the retained natural cleavage site was easily broken.
[0260] Example 5 Enzyme Digestion Method
[0261] For the purified protein obtained in the above examples:
[0262] TEV single enzyme digestion: The purified protein was digested with TEV enzyme in 3 mM GSH, 0.3 mM GSSG at 20-30°C overnight.
[0263] Double enzyme digestion: The purified protein was digested with KLK5 enzyme at 20-30°C for at least 8 hours, and then digested with TEV enzyme at 20-30°C overnight with 3mM GSH and 0.3mM GSSG.
[0264] Example 6 In vitro activity detection experiment of enzyme digestion products
[0265] In order to simply, efficiently and accurately detect the activity of the cleavage product in vitro, we use the fluorescence resonance energy transfer (FRET) method, which transfers photon energy from one excited fluorophore (donor) to another fluorophore (acceptor) when the donor and acceptor are very close to each other (1-10nm). This experiment uses a substrate system with a CFP-substrate cleavage site-YFP structure. When excited with 433nm excitation light under normal conditions, an emission light signal can be received at 527nm (yellow light). When an active cleavage product is present, because the substrate system is cut by the cleavage product, when excited with 433nm excitation light, an emission light signal will be received at 476nm (blue light). The change in the ratio of blue light to yellow light can be used to calculate the activity of the cleavage product in cleaving the substrate.
[0266] (1) Activity effects of double enzyme digestion products on different substrates
[0267] 1. Experimental purpose: To test the cleavage effect of the enzyme cleavage products on the CFP-SNAP25 (17aa) -YFP substrate protein and CFP-SNAP25 (66aa) -YFP substrate protein.
[0268] 2. Experimental Procedure
[0269] 2.1 Reagents
[0270] 2.1.1 HEPES;
[0271] 2.1.2 NaCl;
[0272] 2.1.3 DTT;
[0273] 2.1.4 Zn(OAc)2;
[0274] 2.1.5 Purified water;
[0275] 2.1.6 CFP-SNAP25(17aa)-YFP 1.9mg / mL(55.72kDa);
[0276] 2.1.7 CFP-SNAP25(66aa)-YFP 2.8mg / mL(61.22kDa);
[0277] 2.1.8 Double enzyme digestion 700ug / mL;
[0278] 2.1.9 Na2CO3
[0279] 2.2 Consumables
[0280] 2.2.1 50ml centrifuge tube;
[0281] 2.2.2 384-well ELISA plate;
[0282] 2.2.3 200 μl pipette tip;
[0283] 2.2.4 10μl pipette tip;
[0284] 2.2.5 1.5ml EP tube.
[0285] 2.3 Equipment
[0286] 2.3.1 Microplate reader;
[0287] 2.3.2 1ml pipette;
[0288] 2.3.3 200 μl pipette;
[0289] 2.3.4 10μl pipette;
[0290] 2.3.5 pH meter;
[0291] 2.3.6 Analytical balance.
[0292] 2.4 Determination of substrate cleavage effect
[0293] 2.4.1 Prepare the cleavage reaction buffer: Weigh 0.1835 g Zn(OAc)2 using an analytical balance, then add ultrapure water to make up to 50 ml to prepare a 20 mM Zn(OAc)2 solution.
[0294] 2.4.2 Using an analytical balance, weigh 0.5958 g of HEPEs, 0.0146 g of NaCl, and 0.0154 g of DTT into a 50 ml centrifuge tube. Add 50 μl of 20 mM Zn(OAc)2 solution, and then add ultrapure water to make up to about 45 ml and mix thoroughly.
[0295] 2.4.3 Next, adjust the pH of the solution to 7.4 using 1M Na2CO3 solution. Finally, use a 50ml volumetric flask to fill the cutting buffer to volume to obtain the cutting reaction system.
[0296] 2.4.4 Thaw the two substrate proteins on ice;
[0297] 2.4.5 Turn on the microplate reader and its control computer, and adjust the temperature of the microplate reader reaction chamber to 37 degrees;
[0298] 2.4.6 The final reaction system for each cleavage reaction was 50 μl, and different ratios (concentration ratios) of substrate to double-enzyme cleavage product were set: 8:1; 5:1; 2.5:1.
[0299] 2.4.7 Prepare the final reaction system in a 1.5ml EP tube according to the above ratio: in the reaction system with a substrate: enzyme ratio of 8:1, the concentration of the double-enzyme cleavage product is 140ug / ml, and the substrate concentration is 1120ug / ml; in the reaction system with a substrate: double-enzyme cleavage product ratio of 5:1, the concentration of the double-enzyme cleavage product is 140ug / ml, and the substrate concentration is 700ug / ml; in the reaction system with a substrate: double-enzyme cleavage product ratio of 2.5:1, the concentration of the double-enzyme cleavage product is 140ug / ml, and the substrate concentration is 350ug / ml. The total system is 50ul. After adding the substrate and double-enzyme cleavage product, fill it with cleavage reaction buffer and mix well. Set up two blank controls, one with only CFP-SNAP25 (17aa) -YFP substrate protein and the other with CFP-SNAP25 (66aa) -YFP substrate protein but no double-enzyme cleavage product;
[0300] 2.4.8 After mixing, add the final reaction system to the 384 ELISA plate and shake the plate in a microplate reader for 2 minutes;
[0301] 2.4.9 After vibrating and mixing, adjust the reaction program and read the readings every two minutes for three hours. The readings are set to excitation light 433nm, receiving light 476nm, and excitation light 433nm, receiving light 526nm. Both excitation light wavelengths need to be measured.
[0302] 2.4.10 After 3 hours of reading, remove the plate and add 3 μl of 0.25% Trypsin to each sample well to terminate the reaction. After adding 0.25% Trypsin, place the plate in the microplate reader and begin reading. Read the plate every minute for half an hour. The reading settings are: excitation light 433 nm, reception light 476 nm, and excitation light 433 nm, reception light 526 nm. Both excitation wavelengths should be measured.
[0303] 2.5 Clearance
[0304] 2.5.1 The records are complete.
[0305] 2.5.2 Waste classification and disposal: Waste will be disposed of in chemical waste storage bins.
[0306] 3. Results and Analysis
[0307] Figures 4 and 5 show the substrate conversion rates of different concentrations of substrates CFP-SNAP25 (17aa) -YFP and CFP-SNAP25 (66aa) -YFP, respectively. It can be seen that within a certain time range, the substrate conversion rate is linearly related to time, so the cleavage effect of the double enzyme digestion product on the two is in line with expectations, preliminarily proving that the double enzyme digestion product has an effect in vitro experiment;
[0308] However, the linear relationship of the substrate CFP-SNAP25(17aa)-YFP was significantly better than that of CFP-SNAP25(66aa)-YFP, which means that the substrate protein CFP-SNAP25(17aa)-YFP had a better conversion rate than the substrate protein CFP-SNAP25(66aa)-YFP;
[0309] In addition, Figures 4 and 5 show that the ratio of substrate to double-enzyme cleavage product has a good linear relationship at 8:1 and 5:1, and the ratio of substrate to double-enzyme cleavage product reaches a plateau at about 2 hours at 5:1, while the time for substrate to enzyme ratio at 8:1 is too long, so the subsequent experiments will use a substrate to enzyme cleavage product concentration ratio of about 5:1.
[0310] (2) Effect of TEV single enzyme cleavage
[0311] This study mainly compared the activity effects of TEV single-enzyme digestion products and double-enzyme digestion products to eliminate the influence of TEV enzyme.
[0312] The experimental method is the same as that of "(I) Activity effect of double enzyme cleavage products on different substrates". The difference is that only the substrate CFP-SNAP25 (17aa) -YFP was selected this time. The concentration of the substrate protein CFP-SNAP25 (17aa) -YFP protein in the system was 800ug / ml. The TEV single enzyme cleavage product (stock solution concentration 700ug / ml) and the double enzyme cleavage product were used for comparative experiments. The concentrations of the single enzyme cleavage product and the double enzyme cleavage product were both 140ug / ml (the concentration ratio of substrate to enzyme cleavage product was close to 5:1), and two blank controls were set up with only CFP-SNAP25 (17aa) -YFP substrate protein added but no enzyme cleavage product.
[0313] Figure 6 shows the conversion rate of double enzyme digestion products to substrates within a certain time range.
[0314] It shows a linear relationship, and the TEV single enzyme cleavage product has basically no activity effect on the substrate. This experiment evaluated that the TEV enzyme remaining in the single enzyme cleavage product has no activity on the substrate, and TEV enzyme cleavage does not affect the activity of the single-chain polypeptide.
[0315] (III) Effect of KLK5 enzyme
[0316] This study mainly compared the activity effects of the double-enzyme digestion products and KLK5 enzyme to eliminate the influence of KLK5 enzyme.
[0317] 1. Experimental purpose: This test tests the effect of KLK5 enzyme
[0318] 2. Experimental Procedure
[0319] 2.1 Reagents
[0320] 2.1.1 HEPES;
[0321] 2.1.2 NaCl;
[0322] 2.1.3 DTT;
[0323] 2.1.4 Zn(OAc)2;
[0324] 2.1.5 Purified water;
[0325] 2.1.6 CFP-SNAP25(17aa)-YFP 26.8mg / mL(55.72kDa);
[0326] 2.1.7 Double enzyme digestion product 671ug / mL;
[0327] 2.1.8 KLK5 enzyme 530 μg / mL;
[0328] 2.1.9 Na2CO 3;
[0329] 2.1.10 Tween80.
[0330] 2.2 Consumables
[0331] 2.2.1 50ml centrifuge tube;
[0332] 2.2.2 384-well ELISA plate;
[0333] 2.2.3 200 μl pipette tip;
[0334] 2.2.4 10μl pipette tip;
[0335] 2.2.5 1.5ml EP tube.
[0336] 2.3 Equipment
[0337] 2.3.1 Microplate reader;
[0338] 2.3.2 1ml pipette;
[0339] 2.3.3 200 μl pipette;
[0340] 2.3.4 10μl pipette;
[0341] 2.3.5 pH meter;
[0342] 2.3.6 Analytical balance.
[0343] 2.4 Determination of substrate cleavage effect
[0344] 2.4.1 Prepare the cleavage reaction buffer. Weigh 0.1835 g Zn(OAc)2 using an analytical balance. Add ultrapure water and dilute to 50 ml to make a 20 mM Zn(OAc)2 solution.
[0345] 2.4.2 Using an analytical balance, weigh 0.5958 g of HEPEs and 0.0146 g of NaCl, respectively, into a 50 ml centrifuge tube. Add 500 μl of 20 mM Zn(OAc)₂ solution (the final concentration of Zn(OAc)₂ is 200 μM), followed by 0.1% Tween 80 (50 μl of 100% Tween 80 per 50 ml), and then add ultrapure water to a volume of approximately 45 ml and mix thoroughly.
[0346] 2.4.3 Next, adjust the pH of the solution to 7.4 using 1M Na2CO3 solution. Finally, use a 50ml volumetric flask to dilute the reaction buffer to obtain a reaction system for later use. After dilution, add 10ml of the DTT-free reaction system to each empty tube. Then, weigh the appropriate amount of DTT powder and add it to the reaction system to prepare a 0.5mM DTT buffer system for later use.
[0347] 2.4.4 Thaw the CFP-SNAP25(17aa)-YFP substrate protein on ice;
[0348] 2.4.5 Turn on the microplate reader and its control computer, and adjust the temperature of the microplate reader reaction chamber to 37 degrees;
[0349] 2.4.6 Prepare each final reaction system in a 1.5ml EP tube: the concentration of the substrate protein CFP-SNAP25 (17aa) -YFP protein in the system is 800ug / ml, the concentration of the double-enzyme digestion product is 140ug / ml, and the remaining excess volume is supplemented to 50ul with the above-configured buffer; in the KLK5 digestion group, the substrate protein concentration is 800ug / ml, no double-enzyme digestion product is added, only KLK5 enzyme is added, and the KLK5 enzyme concentration is 1.4ug / ml (consistent with the remaining KLK5 enzyme concentration in the double-enzyme digestion product), and set up two blank controls with only CFP-SNAP25 (17aa) -YFP substrate protein added but no double-enzyme digestion product;
[0350] 2.4.7 After mixing, add the final reaction system to the 384 ELISA plate and shake the plate in a microplate reader for 2 minutes;
[0351] 2.4.8 After vibrating and mixing, adjust the reaction program and read the readings every two minutes for three hours. The readings are set to excitation light 433nm, receiving light 476nm, and excitation light 433nm, receiving light 526nm. Both excitation light wavelengths need to be measured.
[0352] 2.4.9 After 3 hours of reading, remove the plate and add 3 μl of 0.25% Trypsin to each sample well to terminate the reaction. After adding 0.25% Trypsin, place the plate in the microplate reader and begin reading. Read the plate every minute for half an hour. The reading settings are: excitation light at 433 nm, reception light at 476 nm, and excitation light at 433 nm, reception light at 526 nm. Both excitation wavelengths should be measured.
[0353] 2.5 Clearance
[0354] 2.5.1 The records are complete.
[0355] 2.5.2 Waste classification and disposal: Waste will be disposed of in chemical waste storage bins.
[0356] Figure 7 shows that the conversion rate of the double-enzyme digestion product to the substrate presents a linear relationship within a certain time range, while the KLK5 enzyme has essentially no active effect on the substrate. This experiment evaluated the KLK5 enzyme remaining in the single-enzyme digestion product and found no activity on the substrate, demonstrating that the single-chain polypeptide provided by the present invention can be activated by reducing the disulfide bond after enzymatic digestion.
[0357] (IV) In vitro activity detection of multiple first enzyme cleavage sites
[0358] 1. Press the construction: SP-8His-F2-LC-D(F11-F12)-HC-F2-EGFP-8His:
[0359] The difference between this structure and Formula 1 is that D contains two first enzyme cleavage sites, which are as follows:
[0360] The botulinum toxin protein obtained from this example was digested with TEV alone (single digestion), while a double digestion with TEV and KLK5 (HD) and a negative control containing only KLK5 and no botulinum toxin were used for in vitro activity testing.
[0361] 2. Experimental Procedure
[0362] 2.1 Reagents
[0363] 2.1.1 HEPES
[0364] 2.1.2 NaCl
[0365] 2.1.3 DTT
[0366] 2.1.4 Zn(OAc)2
[0367] 2.1.5 Purified water
[0368] 2.1.6 FP1-SNAP25(17aa)-FP2 26.8mg / mL(55.72kDa);
[0369] 2.1.7 Double digestion (HD is digested at both the first and second enzyme cleavage sites): 671ug / mL (Double digestion)
[0370] 2.1.8 Single enzyme digestion (TEV site only): FA: 336ug / mL; FB: 277ug / mL; FC: 110ug / mL; FD: 427ug / mL; HD (first enzyme cleavage site only KLK5): 100ug / mL;
[0371] 2.1.9 KLK5 enzyme 530 μg / mL; 2.1.10 Na2CO3
[0372] 2.1.11 Tween80
[0373] 2.1.12 BSA
[0374] 2.1.13 HCl
[0375] 2.1.14 PMSF
[0376] 2.2 Consumables
[0377] 2.2.1 50ml centrifuge tube
[0378] 2.2.2 384-well ELISA plate
[0379] 2.2.3 200 μl pipette tips
[0380] 2.2.4 10μl pipette tip
[0381] 2.2.5 1.5ml EP tube
[0382] 2.3 Equipment
[0383] 2.3.1 Microplate Reader
[0384] 2.3.2 1ml pipette
[0385] 2.3.3 200 μl pipette
[0386] 2.3.4 10 μl pipette
[0387] 2.3.5 pH meter
[0388] 2.3.6 Analytical balance
[0389] 2.4 Enzyme activity determination process of Jianmei Peptide 150
[0390] 2.4.1 Prepare the enzyme digestion buffer for Jianmei Peptide 150. First, weigh 0.1835 g of Zn(OAc)2 using an analytical balance, then add ultrapure water and dilute to 50 ml with ultrapure water to prepare a 20 mM Zn(OAc)2 solution for later use.
[0391] 2.4.2 Use an analytical balance to weigh 0.5958g of HEPEs, 0.0146g of NaCl, and 0.0154g of DTT into a 50ml centrifuge tube. Add 50ul of a 20mM Zn(OAc)2 solution, then add 0.1% Tween80 (50ul of 100% Tween80 per 50ml system). Then add ultrapure water to make up to 45ml and mix thoroughly. In addition, prepare other buffer systems and test buffer system 2. All other conditions remain unchanged, and Zn(OAc)2 is added. 2+ The concentration was increased 10-fold to 200uM; in the test buffer system 3, Tween80 was not added, and all other conditions remained unchanged, the pH was adjusted to 5 with 1M HCl; in the test buffer system 4, Tween80 was not added, and 1% BSA was added to all other conditions remained unchanged; in the test buffer system 5, Tween80 was not added, and all other conditions remained unchanged, 1% BSA was added, and 1mM PMSF was added.
[0392] 2.4.3 Next, adjust the pH to 7.4 with 1M Na2CO3 solution (the pH in buffer system 2 has been adjusted to 5, so there is no need to adjust the pH again. Adjust the pH of other systems normally). Finally, use a 50ml volumetric flask to make up the volume of the enzyme digestion buffer and set aside.
[0393] 2.4.4 Thaw the FP1-SNAP25 (17aa)-FP2 substrate protein on ice.
[0394] 2.4.5 Turn on the microplate reader and its control computer, and adjust the temperature of the microplate reader reaction chamber to 37 degrees.
[0395] 2.4.6 Each enzyme digestion system is 50ul. This experiment is to verify the active enzymes of 5 single enzyme digestions of peptidase and optimize the enzyme digestion system of peptidase 150.
[0396] 2.4.7 Prepare each reaction system in a 1.5ml EP tube. The concentration of the substrate protein FP1-SNAP25 (17aa) -FP2 protein in the system is 800ug / ml, and the concentration of the fitness peptide 150 is 140ug / ml. The remaining volume is supplemented to 50ul with enzyme digestion buffer. In the KLK5 enzyme digestion group, the substrate protein concentration is 800ug / ml. No fitness peptide 150 is added, only KLK5 enzyme is added, and the KLK5 enzyme concentration is 1.4ug / ml (consistent with the KLK5 enzyme concentration in the double enzyme digestion). Set up two blank controls with only FP1-SNAP25 (17aa) -FP2 substrate protein added but no fitness peptide 150.
[0397] 2.4.8 After mixing, add the reaction system to the 384 ELISA plate and shake the plate in the ELISA reader for 2 minutes.
[0398] 2.4.9 After vibrating and mixing, adjust to the reaction program and read the reading every two minutes for three hours. The reading is set to excitation light 433nm, receiving light 476nm, excitation light 433nm, receiving light 526nm. Both excitation light wavelengths need to be measured.
[0399] 2.4.10 After 3 hours of reading, remove the plate and add 3 μl of 0.25% Trypsin to each sample well to terminate the reaction. After adding 0.25% Trypsin, place the plate in the microplate reader and begin reading. Read the plate every minute for half an hour. The reading settings are: excitation light 433 nm, reception light 476 nm, and excitation light 433 nm, reception light 526 nm. Both excitation wavelengths should be measured.
[0400] 2.5 Clearance
[0401] 2.5.1 The records are complete.
[0402] 2.5.2 Waste classification and disposal: Waste will be disposed of in chemical waste storage bins.
[0403] Figure 8 shows that in the enzyme digestion system containing Tween 80, the double-enzyme-cleaved botulinum toxin has a significant enzymatic digestion effect on the substrate. In the single-enzyme-cleavage test, FA, FB, FC, FD, and HD (which only has one first enzyme cleavage site, KLK5), the botulinum toxin has no enzymatic digestion effect on the substrate (that is, only the TEV enzyme is cleaved, and the two middle enzyme cleavage sites are not cleaved and have no activity). KLK5 has basically no enzymatic activity in the enzyme digestion system containing Tween 80.
[0404] Example 6 demonstrates that the single-chain polypeptide provided by the present invention needs to be cleaved by a highly specific first protease before it can be highly activated due to the presence of the first enzyme cleavage site.
[0405] Example 7 Experiment of product prepared after double enzyme digestion
[0406] (1) Pharmacological efficacy experiments
[0407] A. Experimental procedures of the injection group
[0408] The modified target plasmid obtained in Example 1 was used to prepare a single-chain polypeptide (eluted and purified at pH 8.0) according to the methods of Examples 1-3. The protein obtained by double enzyme digestion in Example 4 was subjected to the following experiments:
[0409] Purchase female CD-1 mice of about 3 weeks old (13-15g) for the experiment. First, transfer the mice to the animal room for 3 days of adaptation. After the adaptation is completed, perform the injection preparation experiment on the mice. Then dilute the stock protein to 1-0.01ng / ml with phosphate buffer to prepare an injection. After the injection is prepared, perform the injection experiment on the mice. Grasp the mouse with your hand, fix the left hind leg of the mouse with your fingers, find the position of the gastrocnemius muscle of the mouse, and inject 50μl of the injection preparation at the position of the gastrocnemius muscle of the mouse. Inject 3 mice as a parallel experiment. After the injection, observe the state of the mouse first. If it is normal, put the mouse back in the cage. Observe and compare the syndactyly of the left and right limbs of the mouse's hind legs every day.
[0410] B. Experimental operation of smear group
[0411] The single-chain polypeptides prepared according to Examples 1-3 and the protein obtained by double enzyme digestion according to Example 4 were mixed with oleic acid, propylene glycol, Tween 80, etc. as a smear preparation (for the configuration of the smear preparation, see Chinese patent application number 202310178312.0), and the following experiments were performed:
[0412] Female CD-1 mice of about 3 weeks old (13-15g) were purchased for the experiment. First, the mice were transferred to the animal room for acclimatization for 3 days. After the acclimatization was completed, the mice were subjected to the smear preparation experiment. After the smear preparation was prepared, the mice were subjected to the smear experiment. First, the mice were anesthetized by intraperitoneal injection of tribromoethanol, and then the hair of the left hind leg of the mouse was cleaned with a pet shaver to expose the gastrocnemius muscle of the mouse. After the cleaning was completed, the mice were smeared with the preparation, and 200μl was applied to each preparation (100μl was applied to the gastrocnemius muscle of the mouse first, and then 100μl was applied after it dried). Three mice were selected for each group of preparations for parallel experiments. After the smearing was completed, the state of the mice was observed, and the mice were put back into the cage after the preparation was dry. The syndactyly of the left and right limbs of the mouse's hind legs was observed and compared every day, and the mice were smeared with the preparation according to the dose of the first application.
[0413] Refer to Figure 2 to score the experimental effects of the two groups of test products: the left side of the figure shows the reference of the unused product, and the right side shows the reference of the changes in the used product. The scores are divided into 0, 1, 2, 3, 4 and 5, a total of 5 levels. The higher the score, the better the effect.
[0414] The experimental results are shown in FIG3 , wherein the injection concentration shown in the figure is 0.3 ng / ml and the smearing histone concentration is 10 μg / ml.
[0415] According to the experimental results, we can see that:
[0416] (1) The injection group showed the strongest drug effect on the third day after a single dose, and the effect was basically restored on the fifth day after administration;
[0417] (2) The smear group was given the drug continuously for 11 days, and the strongest effect was shown on the 5th day after the drug was given. After the drug was stopped, the duration of the drug effect was significantly longer than that of the injection group.
[0418] (2) Acute oral poisoning experiment-gastric gavage experiment
[0419] For the experiment, female CD-1 mice approximately 3 weeks old (13-15 g) were purchased. The mice were first transferred to the animal room and allowed to acclimate for 3 days. After acclimatization, the mice were gavage-treated with the aforementioned injection and smear formulations.
[0420] Specifically, hold the mouse firmly by hand, draw up 300 μl of the injection or smear formulation using a 1 ml syringe, and administer the injection or smear via gavage using a No. 8 gavage needle. Three mice were gavaged in parallel. After gavage, observe the mouse's condition. If normal, return it to its cage. Observe the mouse's behavior daily and record its weight.
[0421] Experimental results: No mice died whether they were injected or smeared, and their weight gain trend was the same as that of the control group.
[0422] Example 8 Experiment without enzyme digestion
[0423] (1) According to the method of Example 1, a target plasmid containing a nucleotide sequence encoding a protein structure as shown in Formula 1 was constructed:
[0424] LC-D-HC (Formula 2, N-terminal to C-terminal connection);
[0425] In the formula, D represents the middle amino acid sequence region, which contains the first enzyme cleavage sites corresponding to several different first proteases, including KLK5, KLK7, SASPase, and Caspase-14. LC represents the first domain, and in this embodiment, the amino acid sequence of LC is SEQ ID NO: 10. HC represents the second domain, and in this embodiment, the amino acid sequence of HC is SEQ ID NO: 17.
[0426] The specific structure is shown in Table 3:
[0427] The amplified products (DNA templates) obtained from the structures in Table 3 were expressed and purified according to Examples 2-3 to obtain the respective proteins.
[0428] Electrophoresis was performed, and the results of the gel run showed that there was no obvious cleavage of the obtained proteins, proving that they were not easily activated when they were not exposed to the specific first protease in vitro.
[0429] (1) Smear test
[0430] 1. Materials and Animals
[0431] 1.1 Sample Information: Each sample protein was prepared at a concentration of 10 μg / ml. All samples were stored in the dark and refrigerated (2°C-8°C). 1.2 Animal Strain: CD1 mice, source: Zhejiang Weitonglihua Laboratory Animal Technology Co., Ltd., 24 female mice, 18-22 g, SPF grade, introduction date: 20230407, Laboratory Animal Production License Number: SCXK (Zhejiang) 2019-0001, Laboratory Animal Quality Certificate Number: 20220714Abzz0619000520, Laboratory Animal Use License Number: SYXK (Shanghai) 2022-0015.
[0432] 1.3 Feed source: Shanghai Proton Biotechnology Co., Ltd., SPF-grade mouse maintenance feed, production license: Shanghai Feed Certificate (2018) 04001.
[0433] 2 Methods
[0434] 2.1 Detection method: The DAS (Digit Abduction Score) was used to assess the degree of denervation in mice, and the score was calculated according to the criteria in Figure 2 .
[0435] 2.2 Test Method: Remove the prepared protein sample and return it to room temperature. Randomly divide the mice into groups and anesthetize them with 2.5% tribromoethanol intraperitoneally. After anesthesia, shave the hair on the gastrocnemius muscle and wipe with 10% ethanol. Apply the test solution to the gastrocnemius muscle of CD-1 mice. Apply 0.2 ml of each sample to three mice for each sample for 7 consecutive days. Observe the mice continuously after application, and record the number of mice dying and syndactyly daily. The intensity of the test effect will be determined according to the syndactyly scoring standard.
[0436] Conclusion: The results show that the proteins in Table 3 can exert their effects earlier and last longer after application compared with controls 1 and 2.
[0437] (2)LD50
[0438] 1. Materials and Animals
[0439] 1.1 Sample information: FfHDS (fitness peptide 150 (Ff), Km-JMT-0150), colorless and transparent liquid, stored in a dark place and refrigerated (2°C-8°C).
[0440] 1.2. Animal strain: CD1 mice, source: Zhejiang Weitonglihua Laboratory Animal Technology Co., Ltd., 25 female mice, 18-22 g, SPF grade, introduction date: 20230217, Laboratory Animal Production License Number: SCXK(Zhejiang)2019-0001, Laboratory Animal Quality Certificate Number: 20220714Abzz0619000520, Laboratory Animal Use License Number: SYXK(Shanghai)2022-0015.
[0441] 1.3 Feed source: Shanghai Proton Biotechnology Co., Ltd., SPF-grade mouse maintenance feed, production license: Shanghai Feed Certificate (2018) 04001.
[0442] 2. Methods
[0443] 2.1 Detection method: Determination of botulinum toxin type A potency according to General Chapter 3533 of Part IV of the 2020 edition of the Chinese Pharmacopoeia.
[0444] 2.2 Test method: With 0.9% sodium chloride solution, Jianmei peptide 150 (Ff) 750ug / mL was diluted to 6 dilutions at the same geometric intervals. After dilution, its concentration was 2ng / ml, 1ng / ml, 0.5ng / ml, 0.25ng / ml, 0.125ng / ml, 0.0625ng / ml, and the corresponding dosage was 38.46ng / kg, 19.23ng / kg, 9.62ng / kg, 4.81ng / kg, 2.40ng / kg, and 1.20ng / kg. 26-30 day old female Kunming mice (SPF grade) were injected with the diluted test solution respectively. A total of 6 test sample concentration gradients were injected. Except for the first concentration injection of 5 mice, 4 mice were injected with each dilution. Each mouse was intraperitoneally injected with 0.5ml and marked as 1, 2, 3, 4, 5, and 6 respectively. The mice were observed for 5 consecutive days after injection, and the death rate of mice was recorded every day. The bioavailability of the test article was calculated based on the dose-response curve of the animal survival rate on day 4.
[0445] 3. Results
[0446] Excel was used for data processing, GraphPad was used for graphing (see Figure 9), and the modified Coulter method was used for calculation:
[0447] LD 50 =log -1 [X m -i(Σp-0.5)]:
[0448] where X m : the logarithm of the maximum dose group; i: the logarithm of the ratio of the high dose to the low dose of two adjacent groups (the difference between the logarithmic doses of two adjacent groups); p: the mortality rate of animals in each group; Σp: the sum of the mortality rates of animals in each group.
[0449] Calculation results: LD50 = 6.8 ng / kg, potency unit is 0.136 ng / U (calculated as 20 g per mouse) (ie LD50).
[0450] The results were far lower than the potency of natural botulinum toxin. (Rossetto, O.; Montecucco, C. Tables of Toxicity of Botulinum and Tetanus Neurotoxins. Toxins 2019, 11, 686. [CrossRef] [PubMed])
[0451] Botulinum neurotoxin ("BoNT," seven immunologically distinct subtypes, AG) and tetanus neurotoxin ("TeNT") are the most toxic substances known by weight, with LD50s ranging from 0.5 to 2.5 ng / kg when administered by the intravenous or intramuscular routes (National Institute of Occupational Safety and Health, "Registry of Toxic Effects of Chemical Substances (R-TECS)," Cincinnati, Ohio: National Institute of Occupational Safety and Health (1996)).
[0452] The toxicity of wild botulinum toxin A (natural botulinum toxin A) is nearly 20 times that of the peptide we designed.
[0453] (3)ED50
[0454] 1. Experimental purpose: ED50 determination
[0455] 2. Experimental Procedure
[0456] 2.1 Reagents and consumables
[0457] 2.1.1 0.9% sodium chloride solution
[0458] 2.1.2 Km-JMT-0150 (FfHDs, fitness peptide 150 (Ff)) 750 μg / mL;
[0459] 2.1.3 26-30 day old female SPF CD-1 mice (Zhejiang Weitonglihua Laboratory Animal Technology Co., Ltd.)
[0460] 2.1.4 1ml medical syringe
[0461] 2.1.5 Purified water
[0462] 2.1.6 50ml centrifuge tube
[0463] 2.1.7 1ml pipette tip
[0464] 2.1.8 200 μl pipette tips
[0465] 2.1.9 10μl pipette tip
[0466] 2.1.10 1.5ml EP tube
[0467] 2.1.11 Mouse feed
[0468] 2.1.12 Corncob Bedding for Mice
[0469] 2.1.13 Mice drinking purified water
[0470] 2.2 Equipment
[0471] 2.2.1 Clean bench
[0472] 2.2.2 1ml pipette
[0473] 2.2.3 200 μl pipette
[0474] 2.2.4 10 μl pipette
[0475] 2.3 Km-JMT-0150 mouse ED50 experimental procedures
[0476] 2.3.1 Preparation before the experiment
[0477] 2.3.1.1 Prepare the disposable medical syringes, CD-1 mice of appropriate age, and Km-JMT-0150 in different concentration gradients required for the experiment.
[0478] 2.3.1.2 Ultraviolet sterilization of the clean bench for 30 minutes.
[0479] 2.3.1.3 Record the information of this experiment in the Animal Experiment Record.
[0480] 2.3.2 Preparation of test samples
[0481] Preparation of different gradient concentrations of Km-JMT-0150: Km-JMT-0150 was diluted to 8 dilutions at the same geometric intervals with 0.9% sodium chloride solution. The concentrations after dilution were 1.68 ng / ml, 0.84 ng / ml, 0.42 ng / ml, 0.21 ng / ml, 0.105 ng / ml, 0.0525 ng / ml, 0.02625 ng / ml, and 0.013125 ng / ml, and were marked as 1, 2, 3, 4, 5, 6, 7, and 8, respectively.
[0482] 2.3.3 Experimental methods
[0483] 2.3.3.1 Select 24 4-week-old female SPF CD-1 mice, weigh them, and observe their living conditions in preparation for gastrocnemius muscle injection.
[0484] 2.3.3.2 Grab a mouse: Grab the mouse by the tail with your right hand, lift it up, place it in a cage or on a laboratory table, and pull it backwards. When it crawls forward, use your left thumb and index finger to grab the mouse's ears and neck skin. Place the mouse in the palm of your left hand, straighten its hind legs, hold the mouse firmly by pressing its tail with your ring finger and its hind legs with your little finger.
[0485] 2.3.3.3 After securing the mice, take 8 different diluted levels of Jianmei 150 and inject them into the gastrocnemius muscle of CD-1 mice. Inject 3 mice for each gradient of Jianmei 150, and the gastrocnemius injection dose is 60μl.
[0486] 2.3.3.4 Observe the mice daily for 5 consecutive days after injection, recording the severity of syndactyly. Calculate the ED50 of the test article based on the dose-response curve of the syndactyly rate on the day of most severe syndactyly.
[0487] 2.3.4 Notes
[0488] 2.3.4.1 When preparing and diluting different gradients of Km-JMT-0150, it is necessary to mix thoroughly and then perform serial dilutions.
[0489] 2.3.4.2 When injecting into the gastrocnemius muscle of mice, be sure to quickly insert the syringe needle into the gastrocnemius muscle 0.3 cm at a 90° angle to the gastrocnemius muscle for injection.
[0490] 2.3.4.3 After the injection is completed, to prevent leakage, slightly rotate the needle and then slowly pull it out.
[0491] 2.4 Clearing the Area
[0492] 2.4.1 Place the injected mice back into their cages, discard the needles into the sharps container, and dispose of other waste into the biohazardous waste bin.
[0493] 2.4.2 Use a 75% alcohol cotton ball to wipe the clean bench surface and wipe it clean.
[0494] 3. Results and Analysis
[0495] Figure 10 is the ED50 response curve of this experiment, which was obtained by plotting the mouse syndactyly (the aforementioned scoring criteria) against the logarithm of the gastrocnemius injection dose. The ED50 of Km-JMT-0150 (the dose resulting in a score of 2) was calculated from the response curve to be 256.9 pg / kg = 0.2569 ng / kg.
[0496] Observations of syndactyly in mice revealed that syndactyly was most severe 48 hours after gastrocnemius muscle injection of Km-JMT-0150. The more severe the syndactyly, the slower the recovery time. Conversely, the milder the syndactyly, the faster the recovery time.
[0497] Calculate the safety margin (LD50 / ED50) of Km-JMT-0150: nearly 27.
[0498] The safety margin of wild-type BoNTA1 is 13.
[0499] It can be seen that we provide a much lower toxicity and better safety margin than wild ones.
[0500] The sequences mentioned above are summarized in Table 4.
Claims
1. A single-chain polypeptide, characterized in that include: The first domain, the middle amino acid sequence region, and the second domain, in, The intermediate amino acid sequence region is between the first domain and the second domain, The intermediate amino acid sequence region sequence contains at least one first enzyme cleavage site, which is designed to be highly specifically cleaved by a first protease present in a specific part of the human body. After being cleaved by the first protease at the first enzyme cleavage site, the single-chain polypeptide is converted into an activated form that can inhibit the release of information substance.
2. The single-chain polypeptide according to claim 1, characterized in that: in, The first domain has a molecular weight of about 50 kDa, the second domain has a molecular weight of about 100 kDa, and the first domain has cleavage activity.
3. The single-chain polypeptide according to claim 1 or 2, characterized in that: in, The information substance is an intercellular information substance, preferably any one of a neurotransmitter, an endocrine hormone, a local chemical mediator, and a gas signal molecule, and more preferably the information substance is acetylcholine.
4. The single-chain polypeptide according to any one of claims 1 to 3, characterized in that: in, The first domain is a protein that can cut the exocytosis fusion apparatus of the target cell. Non-toxic cellular proteases or fragments thereof; The second domain has a binding portion and a transport portion, The binding part can bind to the target cell receptor and enter the endosome of the target cell through receptor-mediated endocytosis, and the transport part can transport the first domain into the cytosol of the target cell; Preferably, the first enzyme cleavage site is between the first domain and the transport portion, and / or the binding portion is carboxyl-terminal and has a molecular weight of about 50 kD, and the transport portion is amino-terminal and has a molecular weight of about 50 kD; Another preferred embodiment is that the protein of the exocytosis fusion apparatus is the neuronal snare protein, and / or the target binding site is a receptor on the presynaptic membrane of the neuron.
5. The single-chain polypeptide according to any one of claims 1 to 4, characterized in that: in, The first domain includes at least a portion of the L chain of the Clostridium neurotoxin: Preferably, the portion of the Clostridium neurotoxin L chain is the neurotoxin L chain of one of Clostridium botulinum subtypes A, B, C, D and E or is derived therefrom, and / or the first domain contains an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to SEQ ID NO: 10, or contains an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of 11-16 except for the naturally occurring enzyme cleavage sequence; and / or The second domain comprises at least a portion of a Clostridium neurotoxin H chain, preferably a portion of the Clostridium neurotoxin H chain is a neurotoxin heavy chain of one of the following: Clostridium botulinum subtype A, Clostridium botulinum subtype B, Clostridium botulinum subtype C, Clostridium botulinum subtype D, Clostridium botulinum subtype E, Clostridium botulinum subtype F, Clostridium botulinum subtype G, Clostridium baratii and Clostridium butyricum; or a portion of the Clostridium neurotoxin H chain is a neurotoxin H chain of Clostridium tetani or is derived therefrom, and / or The second domain comprises an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 17-23.
6. The single-chain polypeptide according to any one of claims 1 to 7, characterized in that: in, The number of amino acids in the linker (L1) between the first domain and the middle amino acid sequence region is 0-20 or 0-10 amino acids or 0-5; and / or The number of amino acids in the linker (L2) between the intermediate amino acid sequence region and the second domain is 0-20 or 0-10 amino acids or 0-5.
7. The single-chain polypeptide according to any one of claims 1 to 6, characterized in that: in, The first protease is not a protease present in the human digestive tract, Preferably, the specific part of the human body is human skin tissue, and / or at least one of the first proteases is selected from the following: Any one or more of epidermal specific kallikrein (KLKs) proteases (e.g., KLK5, KLK6, KLK7), SASPase proteases, Caspase proteases (e.g., Caspase-14), Furin proteases, and their respective variants retaining enzymatic activity; and / or, The first enzyme cleavage site contains an amino acid sequence that is at least 50%, 60%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 1-4, SEQ ID NO: 50 and SEQ ID NO:
51. In SEQ ID NO:50 and SEQ ID NO:51, "X" in RXXR and RRXX is any amino acid, preferably, XX in RXXR is RK, TK or TR; "XX" in RRXX is SV or KR.
8. The single-chain polypeptide according to any one of claims 1 to 7, characterized in that: Also includes: Any one or more of a signal peptide for increasing the expression amount, a quantitative protein for quantification, and a tag protein, Furthermore, one or more of the signal peptide, the quantitative protein and the tag protein are defined as follows: The signal peptide comprises an amino acid sequence that is at least 80%, 85%, 90%, 99% or 100% identical to SEQ ID NO:24; The quantitative protein is a fluorescent protein; The tag protein is one or more of a His tag, a GST tag, an MBP tag and a Strep-tagII tag.
9. The single-chain polypeptide according to any one of claims 1 to 8, characterized in that Also includes: Two second enzyme cleavage sites are respectively located at the N-terminus of the first domain and the C-terminus of the second domain, and the second protease that cleaves the second enzyme cleavage site cannot cleave the first enzyme cleavage site.
10. The single-chain polypeptide according to any one of claims 1 to 9, characterized in that: in, The first enzyme cleavage site and / or the second enzyme cleavage site are usually not cleaved by proteases that are exposed during the expression of the single-chain polypeptide in vivo by a host cell or during the synthesis of the single-chain polypeptide by an in vitro synthesis system involving cell extracts from host cells.
11. The single-chain polypeptide according to claim 9 or 10, characterized in that: in, The second enzyme cleavage site is designed to be highly specific to the second protease, Preferably, the second protease is selected from non-human enterokinase, tobacco etch virus protease, a protease derived from Bacillus subtilus, a protease derived from Bacillus amyliquifaciens, a protease derived from rhinovirus, papain, a homologue of insect papain or a homologue of crustacean papain; and / or The second enzyme cleavage site contains at least one of SEQ ID NOs: 5-9 Amino acid sequences with 85%, 90%, 99% or 100% identity.
12. The single-chain polypeptide according to any one of claims 1 to 11, characterized in that: in, The intermediate amino acid sequence region sequence further comprises XTXS, wherein X is not a K amino acid, and preferably: X is a Q amino acid; and / or The structure of the intermediate amino acid sequence region sequence from N-terminus to C-terminus is: XTXS-linker (L3) - at least one first enzyme cleavage site, further, the number of amino acids in L3 is 0-20 or 0-10 or 0-5, and further, the number of the first enzyme cleavage site is 1.
13. The single-chain polypeptide according to any one of claims 1 to 12, characterized in that: When the second domain contains an amino acid sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 17, the lysine at the position corresponding to the 423rd position of the amino acid sequence of the second domain is mutated to non-lysine.
14. The single-chain polypeptide according to any one of claims 1 to 13, characterized in that: in, The first domain, the middle amino acid sequence region and the second domain are connected from the N-terminus to the C-terminus; and / or When there are multiple first enzyme cleavage sites, the multiple first enzyme cleavage sites are sequentially connected from the N-terminus to the C-terminus, all the first enzyme cleavage sites have the same cleavage site or the first enzyme cleavage sites are different, and the multiple cleavage sites are connected sequentially from the N-terminus to the C-terminus. The number of amino acids in the linker (L4) is 0-20 or 0-10 amino acids or 0-5.
15. Use of the single-chain polypeptide according to any one of claims 1 to 14: The applications include any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms.
16. Use of the single-chain polypeptide according to any one of claims 1 to 14 in the preparation of a product or medicine for a specific purpose: The specific uses include any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms.
17. A single-chain polypeptide product or drug, characterized in that: include: The single-chain polypeptide according to any one of claims 1 to 14, Preferably, the products or drugs have applications including any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms; Another preferred embodiment is that the product or drug is applied to a specific part of the human body by smearing, spraying, external application or injection.
18. A nucleic acid, characterized in that include: A nucleotide sequence encoding the single-chain polypeptide according to any one of claims 1 to 14.
19. A carrier, characterized in that include: The nucleic acid of claim 18.
20. A host cell, characterized in that: The nucleic acid according to claim 18 is integrated and / or the vector according to claim 19 is included.
21. The host cell according to claim 20, characterized in that: The host cell is derived from a prokaryotic cell or a eukaryotic cell. Further, the cell is selected from the following group: a combination of one or more of Escherichia coli cells, human cells, Chinese hamster cells, ovarian cells, insect cells, wheat germ cells, rabbit reticulocytes and yeast cells.
22. The host cell according to claim 21, characterized in that: in, The host cell is selected from yeast cells. Further, the yeast cell is selected from: a combination of one or more of Saccharomyces cerevisiae and Kluyveromyces yeast. In another preferred embodiment, the Kluyveromyces yeast is selected from: a combination of one or more of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii.
23. An in vitro cell-free synthesis system, characterized in that: The single-chain polypeptide is synthesized using mRNA or DNA encoding the single-chain polypeptide according to any one of claims 1 to 14 as a template.
24. The in vitro cell-free synthesis system according to claim 23, characterized in that: Includes any one or more of the following: (1) mRNA or DNA template encoding the single-chain polypeptide; (2) a cell extract, wherein the cell extract is a yeast cell extract, and further, the cell extract is derived from any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris and Kluyveromyces; preferably, the yeast cell extract is derived from Kluyveromyces, more preferably Kluyveromyces lactis; (3) Any one or more of the following components: Amino acid mixture, dNTP, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent.
25. A method for preparing the single-chain polypeptide according to any one of claims 1 to 14, characterized in that: The single-chain polypeptide is obtained by performing an in vitro synthesis reaction using mRNA or DNA encoding the single-chain polypeptide according to any one of claims 1 to 14 as a template, Preferably, the in vitro synthesis reaction is carried out in a reaction system comprising the in vitro cell-free synthesis system according to claim 23 or 24, Furthermore, the volume ratio of the DNA template to other components involved in the in vitro synthesis reaction ranges from 1:10 to 1:50 or 1:20 to 1:40 or 1:25 to 1:35 or 1:
30.
26. The preparation method according to claim 25, characterized in that: in, The cell-free in vitro synthesis system comprises: yeast cell extract, ammonia Amino acid mixture, dNTP, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent; Further: The yeast cell extract is derived from any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris and Kluyveromyces; preferably, the yeast cell extract is derived from Kluyveromyces, more preferably Kluyveromyces lactis.
27. The preparation method according to claim 26, characterized in that: in, The yeast cell extract accounts for 50-80% of the volume of the entire cell-free in vitro protein synthesis system.
28. The preparation method according to any one of claims 25 to 27, characterized in that: Also includes: The obtained single-chain polypeptide including the second enzyme cleavage site is cleaved with a second protease to obtain a single-chain polypeptide including only the first domain, the middle amino acid sequence region and the second domain.
29. Use of the nucleic acid according to claim 18, the vector according to claim 19, the host cell according to any one of claims 20 to 22, and the in vitro cell-free synthesis system according to claim 23 or 24 in preparing the single-chain polypeptide according to any one of claims 1 to 13.
Citation Information
Patent Citations
Kit for in vitro synthesis of protein and preparation method
CN106978349A
Protein synthesis system for in-vitro protein synthesis, kit and preparation method for protein through in-vitro synthesis
CN108535489A
Synthesis system, preparation, kit and preparation method of in-vitro DNA-to-Protein (D2P)
CN108642076A
Novel fusion protein preparation method and application of novel fusion protein for increasing protein synthesis
CN108690139A
Method for regulating in-vitro biosynthetic activity by knocking out nuclease system
CN108949801A
